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Abstract 
 
This study incorporates an experimental and an associated modeling investigation of 
human protective shielding methodologies for two extreme environments: first 
responders or military personnel in the case of nuclear or radiological incidents (360 
Gamma); second a deep space mission (AstroRad). Both solutions utilize selective 
shielding of organs, tissues, and stem cell niches which are relatively more 
radiosensitive to either deterministic or stochastic effects depending on the application 
to derive the greatest biological benefit per unit mass shielding. This is accomplished by 
allocating the shielding over the surface of the body in a variable thickness architecture 
which is inversely related to the radio-density of the intervening tissues between the 
shielding and the organ, tissue, or stem cell niche being targeted for protection. This 
structural design of shielding placed adjacent to the area of the body being protected 
and being of a variable thickness which augments the self-shielding of the body at each 
point on the surface provides the function of optimized use of shielding material to 
reduce the absorbed doses to the organs, tissues, or stem cell niches targeted for 
protection.  
The experimental studies utilized the best available facilities to provide a dose realistic 
environment and the best available phantoms for dose absorption. MCNP6 and HZETRN 
were used for the modeling. In the case of the 360 Gamma, the shielding concept 
experiments matched well with the model. In the case of the AstroRad, experiments 
verifying the simulations are planned for the near future. The work demonstrated 
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significant reduction in absorbed dose to the organs and tissues targeted for protection 
in both cases. 
This study involves human protective shielding in two distinct environments: First, 
human protection for military personnel or first responders to a nuclear or radiological 
incident; Second for astronauts on a deep space mission. The two human protection 
environments will be discussed separately, thereby dividing this dissertation into 2 
distinct but related parts beginning with the 360 Gamma study and results followed by 
the AstroRad study and results because even though there are some commonalities, the 
environments and needs for protection differ. 
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Part 1:  Earth Application 
 
Chapter 1. INTRODUCTION 
 
The biological effects of ionizing radiation exposure are categorized as stochastic or 
deterministic. Stochastic effects describe the probability of radiation induced cancer 
and/or hereditary defects where increased exposure corresponds to a higher probability 
of the effects with some latent onset time. Deterministic effects are thought to occur 
beyond a certain dose threshold and increase in severity with increasing dose. Acute 
exposure can lead to Acute Radiation Syndrome (ARS). Usually, cells are able to repair 
the damage in cases where low doses are received. At higher levels of radiation, 
apoptosis results and cells that are lost as part of normal tissue turnover are not 
replaced because of damage to the stem-cell compartment, leading to tissue failure 
(Stone et al. 2003). Many casualties of the Hiroshima and Nagasaki atomic bombs, and 
many of the firefighters who first responded to the Chernobyl nuclear power plant 
accident, became ill with ARS (CDC Accessed March 23, 2012). The probability of survival 
of those inflicted with ARS decreases with escalating radiation dose. Most of the people 
who do not recover from ARS will die within a few weeks to a few months after 
exposure, with the primary cause of death being the destruction of the body’s bone 
marrow (BM) (CDC 2012). This is exemplified by the Chernobyl firefighters, the majority 
of whom received whole body doses between 0.8 and 10 Gy, and the United Nations 
Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) final report on the 
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disaster concluded that the underlying cause of death of all 28 firefighters who 
succumbed to ARS was from bone marrow failure (UNSCEAR 2000, UNSCEAR 2008).   
BM is comprised of hematopoietic stem cells (HSCs) which are responsible for the 
constant renewal of blood cells (Wang and Wagers 2011). Due to their high rate of 
proliferation, HSCs are especially vulnerable to ionizing radiation, but are endowed with 
remarkable regenerative potential (Dainiak 2002; Greenberger and Epperly 2009; 
Pearce et al. 1952; Valentine et al. 1952; Valentine and Pearce 1952). Owing to their 
central role in blood production, lethal irradiation of HSCs leads to death from severe 
anemia, infection and internal bleeding. This relationship between high doses of 
radiation and HSC apoptosis has led to the use of HSC transplantation as a life-saving 
intervention in cases of acute exposure (Arkin et al. 2006; Alpen and Baum 1958; 
Chertkov et al. 1971; MacVittie 1997; Thomas et al. 1982). This is demonstrable in 
medical practice, where thousands of individuals have undergone supra-lethal Total 
Body Irradiation (TBI) for purposes of cancer therapy, and were rescued by well-
matched BM transplantation (Goldman et al. 1986; Thomas et al. 1982). Indeed, life-
threatening damage may be reversed by BM transplantation in individuals receiving 
doses of radiation of up to 10 Gy (CDC, 2012). At doses > 10 Gy, damage to 
gastrointestinal (GI) tissue may become a limiting factor in survival (CDC Accessed 
March 23, 2012, Barnett et al. 2006). Remarkably, in the common procedure of BM 
transplantation, the number of HSCs extracted from a single active BM site containing 
less than 5% of the donor’s BM tissue is sufficient to support the complete 
reconstitution of the HSC compartment in a lethally irradiated recipient (Thomas et al. 
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1975a, Thomas et al. 1975b). This capacity of BM to expand and replenish is due to the 
high regenerative potential of the HSCs it harbors. 
In contrast to mature blood cells, which are dispersed throughout the body, HSCs are 
confined to the bones, allowing for effective targeted shielding. This has been confirmed 
in several animal models, where sparing the HSC-rich area of a subject receiving 
otherwise full-body irradiation is sufficient to support hematopoietic functions and 
allow survival (Cole et al. 1967;  Jacobson et al. 1951; Stearner et al. 1954; van Bekkum 
and Schotman 1974). Approximately 48% of the human body’s active BM is contained 
within the lumbar vertebrae and the pelvic region (ICRP 2002). This high concentration 
of BM makes the pelvic region an ideal area to shield for preventing the serious 
hematopoietic effects of radiation exposure. 
Stem-cell rich tissues like active BM are also more sensitive to the stochastic effects (i.e. 
cancer) of radiation exposure. The high amount of BM in the pelvic region, combined 
with the presence of the sensitive gastrointestinal system and female gonads in this 
same area of the body allows for the possibility of significantly reducing stochastic 
effects of radiation by limiting radiation exposure to this vital area. Thus, shielding this 
region holds great promise for both acute and protracted exposures. 
 Shielding the human body from gamma rays requires large amounts of material, in stark 
contrast to alpha particles that can be blocked by paper or skin, and beta particles that 
can be blocked by foil. Gamma rays are best blocked using high-Z and high density 
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materials. For this reason, lead is a favorable material for radiation attenuation (Jaeger 
and IAEA 1968).  
A specialized radiation shielding device for the protection of active BM concentrations is 
presented here, which to the best of our knowledge is the first to be developed for 
humans.  This belt-like 360 Gamma focuses on the protection of BM that is present in 
the pelvis and hip bones. The 360 Gamma protects the medullary volume from which 
BM is commonly extracted for transplantation (i.e. the iliac bones) (Thomas et al. 1975a, 
Thomas et al. 1975b) while allowing relatively unhindered movement of the wearer. In 
order to optimize the use of shielding materials towards the protection of active BM, 
the shielding uniquely brings into account the natural shielding properties of human 
tissue, with thickness being inversely related to the thickness and radiation attenuation 
of the underlying tissue at each point surrounding the area being protected. The 
findings resulting from both experimental and simulation testing of this 360 Gamma are 
presented here. 
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Chapter 2. METHODOLOGY 
 
2.1. Engineering of the Active Bone Marrow Shield 
First, the ideal target for protection was identified. HSCs are present in several BM 
locations in the human body, the foremost being the pelvis, sternum, ribs, vertebrae 
and skull. In adults the iliac bones of the pelvis are the most attractive targets for 
protection due to a high content of active BM (225 g), the iliac bones’ relatively small 
surface area to volume ratio, and the positioning of the iliac bones in the pelvic girdle at 
the body’s center of gravity - an ideal anatomical location for weight-bearing purposes 
(Watchman et al. 2007). The iliac bones serving as the source of HSCs in BM 
transplantation validates this choice (Thomas et al. 1975a; Thomas et al. 1975b).  
Since, depending on recipient weight, between 23 and 58 cm3, 24 - 61 g (density of 1.06 
g/cm3) (White 1987), of net active BM is harvested and transplanted on average (after 
deduction of plasma and blood cell infiltrates) (NMDP Standards Committee 1993; 
Pichardo et al. 2007), the 360 Gamma was developed so that a mass of active BM 
corresponding to this volume will remain viable at least up to a radiation dose where 
tissues other than BM sustain major damage. The 2nd most radiosensitive tissue is the 
gut (CDC 2012), and the gut sustains irreversible damage at about 11 Gy (CDC 2012), so 
our shield was engineered to protect this critical volume of active BM at doses as high as 
11 Gy (radionuclide energy dependent), a level which covers most nuclear catastrophes. 
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In nuclear disasters, radioactive materials are presented in the form of nuclear fallout in 
a cloud geometry. This dictated that our shield be able to attenuate radiation emanating 
from all directions, so it was engineered with a circumferential arrangement. The 360 
Gamma is designed to closely wrap around the area of the body containing the BM 
selected for protection. Additionally, the 360 Gamma covers body surfaces, which are 
adjacent to the protected BM in order to sufficiently attenuate any radiation 
approaching the BM through the body of the wearer. To engineer a shield of a weight 
and design that does not limit mobility, an approach that would minimize shield mass 
without compromising protection was necessary. Selectively shielding the iliac bones 
provided an effective means of dramatically reducing shield weight compared to non-
selective strategies, but the optimal shield would incorporate into its design the 
attenuation of the underlying tissue. Also, different tissues (bone>muscle>adipose) have 
different radiation attenuation. This shield accounts for the natural shielding properties 
of human tissue by being of differential thickness inversely related to the thickness and 
radiodensity of the underlying tissue at each point surrounding the target for 
protection. Thus, at any given point on the 360 Gamma the radiation attenuation factor 
is such that it accommodates the variation in tissue thickness and radiation attenuation 
in the circumference of the protected BM, reducing shield mass substantially without 
compromising protection. 
Desired Total Attenuation (AD) was defined such that the surviving volume of viable 
active BM is sufficient to allow for hematopoietic reconstitution after exposure. 
Knowing the radiosensitivity of human HSCs and progenitors and the volume of active 
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BM that is protected by the selective shielding device, formula 1 is used to deduce AD 
(Senn and McCulloch 1970). 
 
   
  
  
                 (1) 
 
   
  
  
                   (2) 
 
Where AD = desired total attenuation; DU = unprotected radiation dose and DV = dose at 
which the percent viability of the BM cell is equal to percent viability of active BM 
necessary for hematopoietic reconstitution (PR). PR = percent viability of active BM 
necessary for reconstitution; VN = volume necessary for reconstitution (23 to 58 cm
3, 
size dependent) and VP = volume of protected active BM. 
The Visible Human Data set was employed to calculate Tissue Attenuation (AT). The 
Visible Human Project is the creation of complete, anatomically detailed, 3D 
representations of the human body (Ackerman et al. 1995; NIH 2012; Spitzer and 
Whitlock 1998; Spitzer et al. 1996). The data set includes complete transverse and 
reconstructed longitudinal cryosection images of representative male and female 
cadavers. This tool, which has been used for the construction of accurate digital 
phantoms in several radio-dosimetry studies, allowed us to measure the thickness and 
determine the overall radiodensity of tissues surrounding active BM sites (Caon 2004; 
Xu et al. 2000). Using cross sectional data from the Visible Human pelvic area (Fig. 1A), 
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an anatomically accurate digital phantom was created (Fig. 1B-D) allowing the mapping 
of the tissue type and thickness present between the selected BM centers and radiation 
entry points for hundreds of points around the waist area. Inputting this data into the 
following formula arrived at the true tissue attenuation at a given point: 
 
             
                 (3) 
 
AT=tissue attenuation; b=build-up factor for one energy at tissue thickness x;  =linear 
attenuation coefficient in cm-1; x = tissue thickness between BM and body surface point 
(x,y,z) in cm. AT and AD then allowed the calculation of the Required Attenuation (AR) of 
the shielding at any given point (equation 4) and subsequently to the shielding thickness 
at any point (equation 5). 
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Figure 1. Pelvic Bone Marrow Building an anatomically accurate digital phantom using The Visible 
Human Project. A. Traverse section through the pelvis of the Visible Human cadaver (Z axis = upper L5). 
The iliac crests are marked with arrows. B-D. StemRad’s digitalization of the Visible Human data set. In B, 
a top view corresponding to A is shown. In C and D a full 3D reconstruction of the torso with bone marrow 
is shown in perspective and side views, respectively. 
 
 
          
  
  
              (4) 
 
                  
        
 
            (5) 
 
This led to a belt-like radiation protection 360 Gamma with variable thickness, using 
only the minimal amount of shielding material needed (Fig. 1). This 360 Gamma in 
combination with the body’s tissue is configured to provide a substantially uniform 4-
fold total radiation attenuation (137Cs) to 300 cm3 of active BM in the posterior pelvis 
and lesser degrees of protection to an additional ~300 cm3 of active BM. The shielding 
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material of the 360 Gamma is provided in the form of multiple uniquely shaped 1 mm 
sheets of virgin lead, which are layered upon each other forming a shielding device of a 
topography inversely related to the thickness and density of the tissue present between 
the 360 Gamma and the protected active BM in the iliac crest.   
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Figure 2. 360 Gamma A. The outer shell of the shielding device is designed for maximal comfort and 
may be worn by use of suspenders. B. The radiation attenuating component of the shielding device is 
comprised of multiple uniquely shaped 1 mm sheets of virgin lead with friction minimizing dividers 
placed between them and multiple other structural elements to maintain flexibility and durability. C. 
The topography of attenuation component matches the anatomy of the underlying BM such that it is of 
a thickness inversely related to the thickness and density of the tissue present between the device and 
the BM, thereby minimizing weight without compromising protection.   
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2.2. Experimental Setup and Configuration 
Irradiations were performed at Pacific Northwest National Laboratory (PNNL) of a male 
phantom that would result in an approximate simulation of a radiation exposure of an 
individual to a cloud-like source of 137Cs. This source-phantom irradiation geometry 
could also simulate the radiation dose to an individual walking and turning numerous 
times in an enclosed environment that contains multiple sources at various heights 
relative to the individual. These irradiations were conducted with the phantom both 
shielded and unshielded with embedded dosimetry to measure changes in absorbed 
doses at internal points of interest (active BM concentrations and abdominal organs) 
resulting from the selective shielding device. 
2.2.1. RANDO Phantom Geometry 
The male RANDO® phantom used for the test irradiations at PNNL, Richland, WA, USA 
was manufactured by Alderson Corporation. The RANDO® man represents a 175 cm tall 
and 73.5 kg male figure without limbs. RANDO® is constructed with a real human 
skeleton that is cast inside soft tissue-simulating material. The phantom is constructed 
of horizontal slices of 2.54 cm thickness to allow access to the thermoluminescent 
dosimeter (TLD) cavities. Each slice contains approximately 40 of these cavities, each 4.8 
mm diameter in a 3.5 cm grid pattern (Fig. 3A). Forty additional TLD cavities were added 
to the RANDO® at specified locations in order to measure the absorbed dose to the 
active BM tissue in the lower spine and pelvis. ImageJ software (Schneider et. al. 2012) 
was used to construct 3D models of the red bone marrow within slices 22-32 of the 
RANDO phantom. The 2D images of each slice face were loaded into the segmentation 
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editor of ImageJ as image stacks and the red BM regions were highlighted as regions of 
interest and interpolated to form 3D volumes of the red BM within the RANDO slices. 
Because of the relative spatial uniformity of the spinal column, the vertebral volumes 
were assigned 1 TLD cavity only for each slice (totaling 7 cavities). The remaining 33 
cavity locations were then identified by calculating the center of masses of 33 equal 
volumes of the pelvic red bone marrow within these slices. This method allowed the 
matching of absorbed doses in these cavities to specific masses of red BM within the 
lower spine and pelvis. These 40 additional cavities were 33 cavities distributed equally 
in the pelvic BM and 7 representing equal volumes of lumbar vertebrae BM.  Another 52 
TLD cavity locations were used to measure doses to the colon, small intestine, and 
ovaries. In total, absorbed doses were measured at 92 distinct cavities in the presence 
vs. in the absence of the 360 Gamma using three lithium fluoride TLDs positioned within 
each of the cavities (Fig. 3B).  
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Figure 3. TLD Cavity Sites within RANDO phantom slices. A. A sample slice demonstrating 
TLD sites. Red dots (right) are additional TLD cavities drilled into RANDO in bone marrow 
concentration sites.  Location of slice in RANDO from external view is shown (right). B. 
The distribution of TLDs within RANDO is shown. 
2.2.2. Structure and Positioning 
 
To ensure precise distances between the source, floor, and RANDO®, a reference point 
was defined near the middle of the torso, at the geometric center on the top of slice 29. 
The z-axis of rotation was relative to this reference point. The 360 Gamma was fit to 
RANDO® with the posterior of the 360 Gamma spanning between slices 24.5 and 33.5. 
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This fit was consistent with the proper donning of the device for ergonomic and 
shielding of the active BM purposes. Fig. 2 shows the 360 Gamma on RANDO® although 
the irradiation was done without clothing. The posterior side of the shielding measures 
18 cm in height and the vertical center of this posterior shielding was positioned to be 
lined up with the reference points in both the RANDO® phantom and the Monte Carlo n-
Particle Code (MCNP) simulations which were also a part of this investigation.  
2.2.3. Source and Irradiation Geometry 
An encapsulated 137Cs source consisting of a total of 0.078” stainless steel and 0.125” 
aluminum was used. Encasing results in the elimination of the beta particle part of the 
spectrum associated with the nuclide, and only the gamma spectrum is seen (peaks at 
662 keV). To create a realistic fallout setting, the source was shifted in relation to the 
phantom to 5 discreet positions (0°, +/- 22.5° and +/- 45°) along the Z-axis relative to the 
reference point, while the phantom itself was rotated at a rate of 1 RPM along the X-Y 
plane. Only the source position near the ground (-45˚) resulted in measurable ground 
scatter (approximately 4.5%), and this was taken into consideration.  
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Figure 4. Experimental Set-up. RANDO phantom embedded with TLDs in bone marrow 
centers, gastrointestinal tissues, and ovary locations were employed to measure total 
integrated dose at specific sites inside the phantom.  The phantom was then subjected 
to irradiation with a 4.85 Curie 
137
Cs (0.662 MeV) source (right). To create a realistic 
fallout setting, the source was shifted in relation to the phantoms to 5 discreet 
positions (0°, +/- 22.5° and +/- 45°) along the Z-axis while the phantom itself was 
rotated at a rate of 1 RPM along the X-Y plane. Precise source-reference position and 
angles are shown.   
 
Post-irradiation, the TLDs were extracted. Doses received at bone marrow 
concentrations, gastrointestinal tissues, and ovaries in the presence vs. in the absence 
of the 360 Gamma were determined on a Harshaw 5500 TLD reader. To determine 
radiation attenuation, the dose recorded in a particular TLD was divided by the ambient 
dose, arriving at the relative dose. Ambient dose was determined based on the in-air 
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kerma measured by a Capintec Model PR-18 ionization chamber at the position which 
the central reference point of the phantom occupied during the irradiations. The dose 
characterization due to the source-phantom geometry as measured by the ionization 
chamber is depicted in Table 1.   
Table 1. Angles, distances and dose rates associated with RANDO and Cs-137 source. 
Source 
Position 
Source 
Height off 
floor (cm) 
Source-Slice 
29 Reference 
Distance 
(cm) 
Source-
RANDO Z-axis 
Distance (cm) 
mR h-1 in 
AIR     
(slice 29) 
mR in 1.6 hrs 
in AIR         
(slice 29) 
+45˚ 300 184 130 379 606 
+22.5˚ 224 141 130 645 1032 
0˚ 170 130 130 759 1214 
-22.5˚ 116 141 130 645 1032 
-45˚ 40 (~4.5% 
scatter) 
184 130 396 634 
                                                                                                  Total Exposure: 4.518 R                      
Total Air-Kerma: 3.967 cGy 
 
2.3. Monte Carlo n-Particle (MCNP) Code Simulations 
 
2.3.1. Simulation of Experimental Conditions 
The experimental conditions were reproduced using the MCNP code and evaluated the 
ability of the 360 Gamma to reduce the dose absorbed in the iliac and vertebral BM 
using point sources of 137Cs. A version of the computerized ORNL-MIRD phantom with a 
modified pelvic and lumbar spine geometry to increase the resolution of absorbed dose 
to the active BM was used (Eckerman et al. 1996). The phantom was positioned 
standing on a concrete slab of 30 cm thickness to allow for ground scatter. Twenty point 
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sources were used in a geometry similar to that used in the PNNL irradiation; at 5 
different heights at 0°, +/- 22.5° and +/- 45° on the z-axis and rotated in 4 positions in 
the x-y plane every 90° relative to the origin (same as ref. point used at PNNL) which is 
the center of torso cell at the height corresponding to where the L-5 vertebra and 
sacrum meet.  
2.3.2. Simulation of Cloud, Ground, and Mixed Source Geometries with Variable 
Energies 
MCNP simulations with more complex source geometries and multiple energies were 
then used to analyze the selective shielding device’s efficacy under conditions of 
interest to first responders. These source geometries included a cloud source, planar 
ground source and an equal combination of the two. All of these simulations used the 
same phantom geometry described above complete with concrete slab.  In the cloud 
source simulation, isotropic photons were generated throughout the volume 
surrounding the phantom, resulting in all possible angles of incidence including above 
the head and just above the surface of the concrete slab. This represents an early-stage 
scenario in which radioactive material has been released into the air but has little to no 
accumulation on the ground. In the planar ground source simulation, isotropic photons 
originated on the surface of the concrete slab at the feet of the phantom representing a 
100% ground source. This represents a later stage scenario in which there is no 
radioactive material present in the air, but it has accumulated on the ground. For the 
1:1 Cloud to Ground source, an equal number of photons originated on the surface and 
volume around the phantom; representing an intermediate situation.      
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At the initial release of fallout, 700 keV (Glasstone and Dolan, 1977) is the average 
photon energy, but this average drops to less than 500 keV within 48 hours (Smith, 
2011). For this reason, the protection provided by the 360 Gamma at these energies is 
also of interest for first responders. Therefore, the cloud, ground and mixed sources 
described were repeated using photon energies of 500 keV, 662 keV, and 700 keV to 
allow for comparison of the 360 Gamma protection factors against the PNNL geometry 
with 137Cs from both the experiment and simulation.  
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Chapter 3. RESULTS  
 
3.1. Experimental Results 
According to PNNL’s formal report for the irradiation testing, the mean relative dose of 
the shielded phantom’s BM volumes divided by the mean relative dose of the 
unprotected phantom’s BM results in a mean belt on/belt off ratio of 0.59 (Murphy1 
2015).  One minus this ratio, 0.41, provides the mean percent reduction in dose to the 
pelvic BM attributed to the 360 Gamma (41%). While the shielding provided by the 360 
Gamma was significant at all pelvic area points studied, it was especially evident in the 
posterior iliac crest which showed a 58% reduction in absorbed dose to the active BM 
from the selective shielding device. This maximum point of attenuation was used to 
calculate the protection factor by which the absorbed dose to a critical mass of active 
BM is reduced by the 360 Gamma resulting in a protection factor of 1/ 0.42 or 2.4. In the 
experiment, the absorbed dose reduction to the total BM tissue in the body was 19%; 
the ovaries had a 35% dose reduction, and the large intestine had a 27% dose reduction 
(Murphy1 2015).  
3.2. Experimental Conditions Simulation Results  
The energy deposition (MeV g-1) reported by F6 tally results for the active BM regions 
represent absorbed doses, which were compared in the shielded and unshielded 
geometries. The maximum reduction in absorbed dose was in a region of the sacrum 
with a 57% reduction compared to the same region in the unshielded phantom, and the 
mass weighted average of absorbed dose reduction for the active BM sampled in the 
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simulation was 42%. The protection factor as defined above was 2.3. In the simulation, 
the absorbed dose reduction to the total active BM tissue in the body was 17%; ovaries - 
29% dose reduction; intestines - 30% dose reduction, and the stomach had a 19% dose 
reduction.   
3.3. Cloud, Ground, and Mixed Source Geometries with Variable Energies Simulation 
Results 
The protection factors for the cloud, ground, and 50/50 Cloud/Ground sources were 
calculated and are shown below in Table 2 along with the protection factors from the 
PNNL simulation and experiment.  
Table 2.  Protection Factors Protection Factors by which the absorbed dose to a critical mass of 
active BM is reduced by the 360 Gamma in all simulation source geometries and the experiment 
done at PNNL. 
 
ENERGY 
(KEV) 
 
 
CLOUD 
50/50 
CLOUD/GROUND 
 
GROUND 
 
PNNL SIM. 
 
PNNL EXP. 
 
700 
 
 
2.0 
 
1.6 
 
1.8 
 
- 
 
- 
 
662 
 
 
2.1 
 
1.7 
 
1.9 
 
2.3 
 
2.4 
 
500 
 
 
2.5 
 
1.9 
 
2.1 
 
- 
 
- 
 
In the cloud, 50/50 cloud/ground and both PNNL geometries, the critical mass of active 
BM with the greatest reduction in absorbed dose was in the iliac crest region. However, 
in the ground simulation, the high angle of incidence from below the phantom resulted 
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in a shift of protection from the 360 Gamma to the critical mass of active BM in the 
lumbar vertebrae.  
3.4. Preservation of Viable Active Bone Marrow Analysis 
Using the attenuation conferred by the 360 Gamma at each point in the pelvic marrow, 
the absorbed dose to active BM assuming an ambient dose of 9 Gy (137Cs) was 
determined. 9 Gy was chosen as a high dose point of interest because it is near the 
maximum dose where the hematopoietic sub-syndrome of ARS is the primary cause of 
death (CDC Accessed March 23, 2012). To this end, it was assumed that the total 
amount of active marrow of our phantom was identical to that of the Computerized 
Anatomical Man (CAM) age corrected for a 25 year-old (1266 g) (Watchman 2007). The 
distribution of the active BM in the body was used to determine how much resided in 
the lumbar spine and pelvic regions (ICRP 2002). Since the TLD cavities were evenly 
distributed through the pelvic volume, the mean absorbed dose of the 3 TLDs in each of 
the 33 pelvic cavities was correlated to a precise mass of active BM.  The vertebral TLD 
cavities’ mean absorbed doses were also applied to the specific masses of active BM 
which they represented. Figure 2 shows the absorbed dose to the active BM histogram 
based on this analysis; a dramatic shift in absorbed dose to active BM is evident in the 
presence of the selective shielding device. Based on the human BM radiosensitivity 
curve (Senn and McCulloch 1970), the precise amount of live active BM that would 
remain following a 9 Gy whole-body exposure in the absence vs. in the presence of the 
360 Gamma (Fig. 2 - red bars) was determined. Adding together the amounts of live 
active BM gave a total of 6 grams for an individual exposed to 9 Gy without protection 
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and 36 grams for an individual equipped with the selective shielding device. This process 
of dose extrapolation to 9 Gy was repeated for the MCNP analysis of the PNNL geometry 
simulation using the shift of absorbed dose to the active BM to determine the amount 
of viable active BM for the shielded phantom and unshielded cases. The results were 
similar to that of the experiment with 33 g of viable active BM in the shielded case and 4 
g for the unshielded. 
 
 
Figure 5. Dose to Active BM at 9 Gy and resulting live BM quantities (shown in red). The 
distribution of absorbed dose to active BM in 50 and 20 cGy dose bins for 
unprotected and protected individuals. 
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Figure 6. Mass of Active Bone Marrow Survival Over High Dose Range Using PNNL Source 
Geometry 
  
Figure 6 above shows a strong level of agreement between the PNNL experiment and 
the MCNP simulation results. This acts to validate that the MCNP model is well 
constructed and predictive of real-world results. This lends credibility to the MCNP 
results for more complicated source geometries and varying energies which were not 
tested experimentally. This source geometries of interest included a cloud source, a 
planar ground source, and varying combinations of cloud/ground.  
3.5. Absorbed Dose Reduction to Organs: All Experimental and Simulation Results  
 
Table 3 shows the absorbed dose reduction percentages for these organs from both the 
PNNL experiment, the MCNP simulation reproducing the PNNL source geometry, cloud, 
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ground, and mixed cloud/ground MCNP source geometry simulations with variable 
photon energies.   
Table 3. Organ absorbed dose reduction in percent to specific organs protected by the selective 
shielding device. All Cloud, Cloud-Ground, and Ground source geometry results are from 
MCNP simulations.   
 Average Organ Absorbed Dose Reduction (%) 
Photon 
Energy 
(keV) 
Source 
Geometry 
Ovaries Intestines Stomach Total 
Body 
Active 
Bone 
Marrow 
662  PNNL 
experimental* 
35 26 N/A 19 
662  PNNL MCNP 
simulation 
29 30 19 17 
500 Cloud  30 30 21 17 
500 50% Cloud - 
50% Ground  
14 20 23 13 
500 Ground  1 6 29 6 
662 Cloud  29 22 17 15 
662 50% Cloud - 
50% Ground  
14 15 20 11 
662 Ground  1 6 26 4 
700 Cloud  24 22 17 14 
700 50% Cloud - 
50% Ground  
11 14 19 11 
700 Ground  0 3 24 4 
*(Murphy1 2015) 
In the case of the total active bone marrow, only a fraction of total tissue in the body 
has been protected through selective shielding, so the mean reduction in dose has been 
multiplied by the fraction of protected active bone marrow divided by total active bone 
marrow. 
In the case of the absorbed dose reduction to the intestines in the PNNL experiment, 
the absorbed dose reductions for the colon and small intestine were measured 
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separately as 27.0% and 25.7% respectively but were averaged in Table 3 for the sake of 
comparison to the simulation. See Appendix V for complete table showing cloud/ground 
source geometry results at 10% increments.  
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Chapter 4. DISCUSSION 
 
4.1. Effect of Energy and Source Geometry Shift 
 
The data contained within Table 3 and Appendix V reveal many things. First, it shows the 
shows the stochastic benefits imparted by the 360 Gamma for various source 
geometries and average photon energies by reducing the absorbed doses to several 
radiation sensitive organs: the ovaries, intestines, stomach and total body bone marrow.  
Especially for the intestines and bone marrow there is also deterministic effect 
implications. While the dose reduction to the bone marrow is a focus of other sections 
of this dissertation, the additional benefit of the reducing the absorbed dose to the 
gastrointestinal system should not be overlooked.   
The reduction in absorbed dose to the stomach is also significant from a deterministic 
effect perspective because of the role that the enterchromaffin-like cells of the gastric 
mucosa (Garau et. al. 2011) play in the prodromal phase of ARS at lower doses for 
symptoms such as nausea and vomiting which could potentially render personnel 
unable to conduct field tasks and effectively remove emergency responders from duty 
during a response to a catastrophic event where response forces are likely to already be 
short staffed. 
An expected trend in dose reduction provided by the 360 Gamma decreasing with 
increasing photon energy is seen here which is expected as higher energy photons are 
more penetrating through matter. 
Another trend seen in this data which is incredibly interesting is that the as the 
radioactive material transitions from 100% cloud to 100% ground, the dose reduction to 
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the total bone marrow, ovaries, and intestines decrease while the dose reduction to the 
stomach increases. However, for this source geometry (planar ground) the legs and the 
distance from the ground offer tremendous attenuation to the active bone marrow. In 
ICRP 89 (ICRP, 2002. Basic Anatomical and Physiological Data for Use in Radiological 
Protection Reference Values. ICRP Publication 89. Ann. ICRP 32 (3-4).) the distribution of 
active bone marrow in the body shows that for an adult, the closest active bone marrow 
to the ground while standing erect is in the upper half of the femora meaning that out 
of all of the active bone marrow in the body, this particular region is the most exposed 
for a ground source-geometry. Using the Oak Ridge National Laboratory computerized 
phantom as an example (Eckerman K.F., Cristy M., Ryman J.C. (1996) The ORNL 
mathematical phantom series, informal paper, OakRidge, TN:Oak Ridge National 
Laboratory. available at http://homer.hsr.ornl.gov/VLab/mird2.pdf) this region is about 
70 cm from the floor level when the adult male is standing erect. 70 cm is a significant 
distance compared to a cloud or cloud-like source geometry where gamma emitters 
may be much closer to the active bone marrow higher on the body. Assuming tissue 
shielding of water for this 70 cm (legs), the dose from a gamma source directly under 
the feet would be reduced to as low as 3.5% of the floor value for 662 keV photon 
energy (Cs-137). This is for the most exposed region of active bone marrow which 
accounts for only 7.4% of the active BM in the entire body (ICRP 89). The dose reduction 
for other active BM sites is even higher of course due to increased distance and 
shielding provided by the body. Therefore, the dose reduction to the bone marrow from 
a deterministic effect perspective becomes less critical relative to a cloud or cloud-like 
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source where there is potentially far less distance and body tissue shielding between the 
source(s) and the active bone marrow.  
 4.2. Effect of the 360 Gamma on ARS Mitigation  
HSC transplantation (i.e. bone marrow transplantation) can be a life-saving intervention 
in cases of exposure to high doses of radiation (Alpen and Baum 1958; Arkin et al. 2006; 
Chertkov et al. 1971; MacVittie 1997; Thomas et al. 1982). The bone marrow quantities 
used in the current practice of transplantation of irradiated human recipients to find 
that, depending on the recipient weight, between 24 and 61 grams of net active bone 
marrow is harvested and transplanted on average (after deduction of plasma and blood 
cell infiltrates) (Pichardo et al. 2007 and National Marrow Donor Program).   
By selectively shielding the bone marrow of the lumbar spine and pelvic region, the 
device is able to preserve in excess of the quantity of active live marrow necessary for 
the reconstitution of a lethally irradiated average sized adult even at exposures as high 
as 9 Gy (36 g and 33 g respectively for the measurement and the simulation).  This is in 
sharp contrast to the unshielded results where beyond 5 Gy of exposure less than 30 g 
of viable active BM remained in both the PNNL experiment and PNNL geometry MCNP 
simulation.  This suggests that the wearing of the 360 Gamma during a high dose 
exposure would have similar benefits to that of a successful bone marrow transplant 
post-exposure without the difficulties of donor matching in the case of allogenic 
transplantation. 
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Not only is this critical mass of viable active BM preserved up to 9 Gy, but the protection 
factors shown in Table 2 ensure that critical masses of active BM remain viable at all 
doses below 9 Gy for all geometries in the energy range investigated (up to 700 keV 
average photon energy). The protection of large portions of BM combined with a 26% 
reduction in absorbed dose to the intestines reduce the morbidity and mortality 
probability associated with ARS.  
The 360 Gamma is also highly likely to reduce the symptoms of nausea and vomiting in 
the prodromal phase of ARS. This is due to the ~20% dose reduction (see Table 3 and 
Appendix V) to the enterochromaffin-like cells of the gastrointestinal tract found in the 
gastric glands of the gastric mucosa beneath the stomach epithelium which are believed 
to be responsible for these prodromal phase symptoms of ARS (Garau et al. 2011).      
4.3 Effect of the 360 Gamma on Radiation-Induced Cancer Reduction   
In addition to the mitigation of the hematopoietic sub-syndrome of ARS, the 360 
Gamma also offers protection against the stochastic effects of radiation exposure. This 
is accomplished through the absorbed dose reduction provided by the 360 Gamma to 
the organs in the abdominal area including the ovaries in females, small and large 
intestine/colon, stomach and total body active bone marrow shown in Table 3. By 
reducing the absorbed doses the to the total active bone marrow, stomach, ovaries 
and colon which are all relatively prone to radiation-induced cancer incidence, the 360 
Gamma is a valuable tool from an ALARA perspective.  
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1The work at PNNL was performed under the Work for Others Program, and any research 
results which were generated are experimental in nature.  Neither the United States 
Government, nor any agency thereof, nor Battelle Memorial Institute, nor any of their 
employees, makes any warranty, express or implied, or assumes any legal responsibility 
for the accuracy, completeness, or usefulness of any information, apparatus, product, or 
process disclosed, or represents that its use would not infringe privately owned rights.  
Reference to any specific commercial product, process, or service by its trade name, 
trademark, manufacturer, or otherwise, does not constitute or imply an endorsement or 
recommendation by the United States Government or any agency thereof, or by Battelle 
Memorial Institute.  The views and opinions of authors expressed herein do not 
necessarily state or reflect those of the United States Government or any agency thereof, 
or by Battelle Memorial Institute and shall not be used for advertising or product 
endorsement purposes. 
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Part 2: Deep Space Application  
 
Chapter 1. INTRODUCTION 
 
The AstroRad is a personal protective equipment (PPE) device which functions as a 
radiation shield for astronauts. The AstroRad shields astronauts from space-borne 
ionizing radiation in an efficient way, provides operational simplification, and allows for 
the use of recycled material on-board the vehicle. The concept behind the AstroRad 
evolved from a commercially available device, the 360 Gamma shield, made by StemRad 
Ltd., which is an effective wearable shield for first responders to radiation incidents on 
the Earth.  The shield selectively protects the pelvis and its repository of bone marrow, 
the largest concentration of hematopoietic stem cells (HSCs) in the body from 
penetrating gamma rays.  By selectively protecting the stem cells, the body can recover 
quickly from Acute Radiation Syndrome (ARS) with a minimal amount of shielding 
material.   
The natural space radiation environment of concern to human space flight is different, 
consisting primarily of high energy ions from two principal sources – solar particle 
events (SPEs) and Galactic Cosmic Rays (GCRs) (Schimmerling, 2011).  Health hazards 
due to ionizing radiation exposure in space consist of stochastic and deterministic 
effects. While deterministic effects from acute exposures typically manifest almost 
immediately, stochastic effects can manifest years or decades after radiation exposure, 
and the increased risk protracts over the remainder of the astronauts’ life.   
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Radiation and synergistic effects of radiation may place the crew of a space mission at 
risk for stochastic effects of radiation such as cancer. In thinly shielded spacecraft or 
during extravehicular activities (EVA), high intensity SPE may even jeopardize mission 
completion and crew health by induction of Acute Radiation Syndrome (ARS).  
When astronauts venture beyond low Earth orbit (LEO), they leave the protection of the 
Earth's atmosphere and magnetic field. Therefore, appropriate shielding and protective 
mechanisms are necessary in order to prevent acute exposures and reduce cumulative 
exposures as low as reasonably achievable (ALARA). This need is amplified in longer 
missions which plan to send humans to Mars over the next decades. 
Humans succumb to ARS from radiation doses as low as 1 - 2 Gy (Fujita et. al. 1991). 
Remarkably, upon exposure to doses of up to 10 Gy, stem cell-rich bone marrow is the 
only tissue to be irreversibly damaged, presenting a survival-limiting factor (CDC, 2012). 
Historically, people suffering from ARS were rarely exposed to doses in excess of 10 Gy. 
In space, ever since solar particle events (SPEs) have been monitored, the largest SPEs 
would have resulted in no more than 4 Gy of radiation to an unprotected astronaut in 
their path.  Thus, a great percentage of the casualties resulting from exposure to 
ionizing radiation in an intense SPE may be avoided by shielding bone marrow from 
radiation. At radiation doses higher than 10 Gy, the small intestine and lungs may be 
irreversibly damaged (Fujita et. al. 1991). 
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In its effort to protect emergency personnel from radiation, StemRad has gone against 
conventional wisdom that in order to protect one must shield as much of the body as 
possible. StemRad’s approach is to protect bone marrow selectively. Due to the 
extraordinary regenerative potential of bone marrow hematopoietic stem cells, to 
ensure marrow function it is unnecessary to protect all or even most of the bone 
marrow. This is exemplified in transplantation, where only a fraction of the donor’s 
bone marrow (<5%) is sufficient to rescue a lethally irradiated recipient. Accordingly, 
StemRad has determined the minimal amount of bone marrow required for recovery 
post-irradiation, and through careful anatomical study, has devised a product that is 
able to protect a bone marrow quantity in excess of this amount. 
Being selective, StemRad’s shielding blocks high energy ionizing radiation while 
remaining of a manageable weight and volume. For further weight and volume 
reduction, StemRad’s product uniquely brings into account the natural shielding 
properties of human tissue, by being of a thickness inversely related to the thickness 
and radiodensity of the underlying tissue at each point surrounding the area being 
protected.  This product has been coined the ‘StemRad 360γ’.  
By effectively shielding the marrow, the 360γ ensures the survival of a sufficient number 
of hematopoietic stem cells, thereby providing a dramatic increase in user survivability. 
The Nuclear Energy Agency (NEA) of OECD recommends use of bone marrow selective 
shielding to mitigate deterministic effects in severe accident management 
(NEA/CRPPH/R (2014)). 
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Selectively shielding stem cells enables regeneration of damaged tissue, thereby 
alleviating the deterministic effects of exposure. At the same time, we suggest that 
shielding stem cells and progenitor cells also provides a disproportionate advantage in 
reducing the stochastic effects of exposure. This is due to the disproportionate progeny 
size of a stem or progenitor cell compared with a differentiated cell. Thus, a stem cell 
harboring a mutation will pass this mutation on to a disproportionately large number 
daughter cells, thus increasing the frequency of mutated cells in an organ and the 
probability of malignancy in that organ. 
To successfully adapt the principles which made the 360γ effective and efficient, the 
AstroRad is being designed significantly different.  First, it must be made to effectively 
shield from the protons and heavy ions space radiation is comprised of. While heavy 
metals such as lead (Pb) constitute the most effective shielding for gamma radiation and 
X-rays, low-Z materials are preferable for shielding of high energy ions. Second, the 
AstroRad must be optimized to reduce cumulative doses received in not only the bone 
marrow but also to other radiation sensitive organs.  
NASA quantifies stochastic risks of radiation exposure in terms of Radiation Exposure 
Induced Death (REID), and currently limits the risk of REID to astronauts to 3% (i.e., 3% 
additional risk of developing fatal cancer over the general population baseline) 
(Cucinotta et. al. 2013).  This risk limit in turn is associated with maximum acceptable 
levels of exposure to ionizing radiation.  Consistent with NCRP recommendations, the 
biophysical quantity Effective Dose is used to define radiation exposure limits.  These 
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limits are gender- and age specific to account for significantly higher radiation 
susceptibility of young female population vs. less susceptible older males.  Design 
requirements imposed on NASA’s next generation exploration-class spacecraft, the 
Orion Multi-Purpose Crew Vehicle (MPCV), are consistent with providing protection to 
the entire astronaut core, including its most susceptible segment, to maintain risk of 
REID at or below 3% for the current design reference missions. These requirements also 
prevent risk of any clinically significant detrimental radiation effects. 
StemRad’s strategy of partial shielding of critical stem cell-rich tissues has been 
expanded to also include other radiosensitive organs beyond bone marrow to also 
include the lungs, colon, stomach, and gonads. This approach is intended to maximize 
the biological effectiveness of shielding materials by reducing radiation exposure to 
critical stem and progenitor cell niches, thereby virtually eliminating the probability of 
deterministic effects and concomitantly reducing REID due to stochastic effects.  
The AstroRad research and development project is a collaborative effort between 
Lockheed Martin and StemRad. Refinements will include physical modification of the 
vest to cover additional sensitive organs, and the inclusion of novel nanomaterials in the 
design.   AstroRad is currently in its second year of research and development with 
strong simulation results using HZETRN code proving its feasibility. Ergonomic testing is 
also underway to ensure it is compatible for use inside spacecraft. Future plans include 
testing prototypes at NASA Space Radiation Laboratory (NSRL) and aboard Orion 
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Exploration Mission 1 (EM-1). Should it prove to be effective, it may be used in planned 
cis-lunar and Mars missions. 
 
Chapter 2. SPACE RADIATION  
 
2.1. Introduction 
 
Interplanetary space represents a harsh environment for human exploration.  The 
natural ionizing radiation environment is no exception.  Space radiation has distinct 
physical properties from most sources of ground radiation, thus requiring innovative 
radiation protection strategies that account for the different physics of interaction of 
charged particles with matter, different biological responses, and practical constraints 
inherent to space exploration including limited lift-off mass.  Any amount of exposure to 
the space ionizing environment is considered detrimental to crew health.  The 
occurrence pattern and severity of the adverse effects is driven by exposure levels.  At 
low dose, the health effects occur stochastically.  This is, increased exposure leads to 
increased probability for radiation effects; stochastic radiation effects include cancers 
and their severity may include fatal forms. Stochastic effects are late effects that may 
manifest clinically only years or decades after exposure.  Increased radiation exposure 
leads to deterministic effects.  These include prompt effects (manifesting within hours 
after exposure) of severity that increases with exposure levels. 
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Natural space radiation environment consists of Galactic Cosmic Rays (GCR), Solar 
Particle Events (SPEs) and trapped radiation (i.e., the van Allen radiation belts).  While 
these three components all consist of charged particles, their intensity, timing, particle 
atomic number and energy spectra render them vastly different in terms of health 
effects and crew protection strategy.  GCR consist of extremely energetic particles 
(spectrum peaking around 300 MeV/nucleon).  While the biological effects of SPEs are 
known to be similar to x-rays and γ-rays, no solid data are available to estimate the 
impact of exposure to long-term GCRs.  An accepted estimation predicts 60% percent of 
astronaut cancer risks are from five GCR ions (C, O, Mg, Si, and Fe) with an additional 
30% from the remaining HZE ions and about 8% from GCR protons. Because of the high 
energy, passive shields have little success stopping GCR.  On the contrary, interaction of 
GCR with high-Z materials results in significant secondary radiation being generated by 
atomic interactions / fragmentation that may be more detrimental than the primary 
particles.  GCR constitute a quasi-constant radiation background modulated by the solar 
activity over solar cycle duration of ~11 years (Kim et. al. 2009).  Due to their low level, 
GCR do not pose a significant risk for short-term space travel and their consequences 
are solely stochastic in nature.  Conversely, GCR exposure is sometimes considered to 
represent the most significant barrier to long duration space travel for which no 
mitigation is known at fundamental scientific level.  Solar Particle Events (SPEs) 
represent massive eruptions of energetic particles, mostly protons, from the Sun.  The 
solar particle energies are lower than those of GCR, thus making SPEs more responsive 
to passive shielding.  NASA requirements imposed on the Orion spacecraft design are 
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consistent with the Agency policy of limiting the astronaut risk of REID (Radiation 
Exposure Induced Death, i.e., additional risk of fatal cancer over the general population 
baseline) to 3% for a conservative choice of astronaut population (i.e., young female) 
(Cucinotta et. al. 2013).  These requirements also prevent risk of any clinically significant 
detrimental effects due to radiation exposure.  Van Allen belt (trapped) protons have 
similar spectra with those emitted during SPEs.  Radiation exposure during van Allen 
belt transit is trajectory dependent, and lunar transit trajectories typically considered do 
not result in considerable loiter in the proton belts.  However, the Orion EFT-1 trajectory 
exposed the spacecraft to peak proton fluence rate (i.e. flux) environment on the same 
order of magnitude as expected during major SPE.     
2.2. High intensity SPE probability and consequences  
 
The ability to predict SPEs is limited. While SPEs are more probable around Solar 
Maximum, they can occur at any time during the solar cycle.   Agencies such as the 
National Oceanic and Atmospheric Administration (NOAA) Space Weather Prediction 
Center (SWPC) monitor solar regions with sunspots, their magnetic properties and 
phasing with respect to Earth and produce forecasts extending over duration on the 
order of days. Satellite assets such as GOES monitor solar X-rays as precursors of solar 
flares and coronal mass ejections (CMEs), and the solar proton flux.  NOAA issues proton 
event alerts based on proton flux exceeding certain thresholds in the energy bands >10 
MeV, and >100 MeV, respectively.   NOAA Solar Radiation Storms scale is based on the 
E>10 MeV band.  Per this scale, severe or extreme radiation storms occur at an average 
44 
 
frequency of 3-4 per 11 year solar cycle (Kim et. al. 2009).  Solar cycles 19-23 
(representing the last 53 years of monitoring) have recorded 14 SPEs with an excess of 
109 protons/cm2 (> 30 MeV) which averages to 0.264 significant events/year (Usoskin et. 
al. 2012). Minor, moderate or strong storms occur at higher cumulative frequency 
averaging 85 per solar cycle (Kim et. al. 2009; Usoskin et. al. 2012).  Energetic Solar 
Particle Events are sub-class of SPEs defined by the high energy particle flux (E>100 
MeV/u) exceeding 1 particle flux unit (pfu).  Such events pose the highest risk for 
manned space missions outside low Earth Orbit, due to the thicker spacecraft shielding 
required to stop higher energy particles as well as the increased probability for 
secondary radiation to be generated by particle interaction with the spacecraft 
structure.  The August 1972 and October 1989 solar particle events are examples of 
intense energetic solar particle events (Cucinotta et. al. 2005; Mewaldt, 2006).  While 
the majority of SPEs consist mostly of protons, the Oct 1989 event contained a 
significant population of heavy ions and had a harder spectrum (i.e., more energetic) 
than the more intense (i.e., higher fluence) Aug 1972 SPE.  For these reasons, the Oct 
1989 event is typically chosen as reference environment for spacecraft hardware 
radiation hardening activities, while the Aug 1972 event is often referenced for 
purposes of crew radiation protection. 
Keeping radiation exposure ALARA (As Low As Reasonably Achievable) is a key radiation 
protection principle.  As no amount of radiation exposure is considered “safe”, NASA 
requirements specifically mandate providing most radiation protection to the crew that 
is achievable within other design constraints.  As such, the not-to-exceed levels derived 
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from the 3% REID risk are not to be considered tolerance levels; instead, any additional 
radiation protection enhancements that can be provided to the crew are in scope of the 
requirements.  
2.3. Stochastic Effects 
NASA calculates Radiation Exposure Induced Death (REID) percent as a way of weighing 
the risks associated with the radiation exposure in space. Not all astronauts are equally 
susceptible to the radiation environment and this is reflected in the differing REID % for 
different sexes and ages of astronauts for any given mission as seen in Cucinotta et. al. 
2010. The dose equivalent which is equal to a 3% REID for male and female astronauts 
of various ages is presented there. For a 30 year-old male, 3% REID is reached at an 
effective dose of 620 mSv while it is only 470 mSv for a female of the same age 
(Cucinotta et. al. 2010). For 40 year-old astronauts, 3% REID is reached at 800 mSv for 
male and 620 mSv for female.   
NASA currently limits astronaut exposure to 3% REID threshold regardless of age or sex. 
This highlights the need for radiation protection solutions as according to current 
projections it is not a simple ideal to achieve, especially for missions to Mars. 
GCR flux for 200 MeV nucleon-1 vary by about a factor of 5 times over the Sun’s 11-year 
sunspot cycle, and this solar modulated GCR flux is inversely related to the sunspot 
number (Martin, 2008). Therefore, GCR doses are lowest during solar maximum and 
highest during solar minimum. Conversely, the probability of encountering a high 
intensity SPE increases greatly during solar maximum.    
46 
 
Tables presented in Cucinotta et. al. 2005 show doses and REID % for male and female 
astronauts at age 40 for lunar-long, Mars swing-by, and Mars surface missions with 20 
g/cm2 aluminum shielding during a period of solar minimum activity and also during a 
period of solar maximum activity (lower GCR flux) with the assumption that a high 
intensity SPE occurs (one equal to the 1972 SPE event) (Cucinotta et. al. 2005).  
Lunar-long missions were defined as 90 day missions with 6 days in deep space and 84 
days on the lunar surface. Mars swing-by was defined as 600 total days in deep space. 
Mars surface mission was defined as 1000 total days with 400 in deep space and 600 on 
the Martian surface (Cucinnota et. al. 2005). 
The lowest REID % of these scenarios by far is found in the scenarios during a period of 
solar maximum activity including the 1972 SPE equivalent occurrence. While both sets 
of scenarios include equal amounts of shielding (20 g/cm2 aluminum), the REID numbers 
at solar maximum even with a significant SPE occurrence are much lower/better (e.g. 
2.5 REID % compared to 3.9 REID % in the case of the female for the Mars swing-by 
mission and 2.0 vs. 3.2 REID % for the male) (Cucinnota et. al. 2005). A high amount of 
the exposure in this case (solar maximum with SPE) comes from the SPE which, although 
of high intensity, is lower in energy than GCR and thus more effectively mitigated 
through passive shielding. This emphasizes the importance of shielding solutions for SPE 
for radiation induced cancer and overall REID %.  
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Chapter 3. RADIATION SHIELDING PROPERTIES  
 
3.1. Desired Material Properties for Shielding 
The energy loss of an energetic particle traversing matter is quantified by the quantity 
linear stopping power S.  In the first order, shielding properties of a material can be well 
quantified by the density-normalized mass-stopping power S/rho.  For a material of 
atomic number Z and mass number A, an approximation the Bethe-Bloch formula shows 
S/rho is proportional to Z/A (Beth and Ashkin, 1953).  This indicates Hydrogen as the 
best material to be used for shielding, a factor of at least 2x more effective in slowing 
down the primary charged particles than any other material in the periodic table.  Z/A 
decreases with increasing Z, rendering high-Z materials typically used for radiation 
shielding in terrestrial applications (e.g., lead) a poor choice for charged particle 
radiation shielding applications.  In addition to electronic interactions, highly energetic 
GCR particles can also interact with the shield material via nuclear collisions, creating 
secondary particles such as neutrons and other nuclear fragments.  Neutrons are long 
range particles that are highly effective in creating biological damage (Q = 20).  The 
neutron generation cross-section is smaller for low-Z materials, further improving the 
relative merit of a hydrogen rich material shield vs. high-Z materials.  
Choice of shielding material for space applications must also consider practical 
constraints.  Some of these constraints are safety related, such as material flammability, 
toxicity, out-gassing, other hazards to human health.  While light, hydrogen-rich 
materials have better density-normalized shielding properties, materials used in the 
design of an individual radiation shield must be of adequate density to limit the physical 
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thickness of the shield while providing sufficient shielding mass (i.e., areal density) to 
meet ergonomic requirements.   
3.2. Candidate Materials 
Traditional materials considered for radiation shielding include high-density 
polyethylene (HDPE) and water.  Water is especially desirable because of its availability 
on manned spacecraft which in turn reduces the need for dedicated radiation shielding 
lift-off mass.   
Hydrogen is unique in its interaction with HZEs, because it cannot fragment into smaller 
nuclei.  Its high effective electron density and relatively high ionization energy mean 
that composites with high-H loading are favored for radiation protection approaches.  
Polyethylene (C2H4)n contains 14% H by mass fraction; therefore nanomaterial 
composites using a polyethylene matrix are particularly attractive as a primary 
component in a novel shielding material. 
Boron also has high potential for inclusion in a space radiation shielding material. It is 
simultaneously low-Z with a relatively high density (2.3 g/cm3) with a natural isotopic 
abundance of 10B of 19.9% which has an extremely high capture cross section for low 
energy neutrons (Martin, 2008). This makes the inclusion of boron advantageous in 
terms of reducing secondary neutron doses and increasing areal density of shielding for 
a given thickness. Boron may be included in the form of a filler in a hydrogen rich 
material such as polyethylene or hydrogenated boronitride nanotubes which have 
desirable material properties as well (Zettl and Cohen, 2010).  
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For some coverage areas on the human body (e.g. groin and joints) require greater 
degrees of flexibility and are less conducive to significant shielding thickness. For these 
areas, aqueous solutions consisting largely of water with additives to increase bulk 
density are also being investigated.   
3.3. Potential Shielding Material Advancements  
 
Advanced material engineering provides opportunities to increase the relative fraction 
of hydrogen per unit mass.  Today’s state-of-the-art manufacturing and nanomaterial 
synthesis approaches have matured to a level sufficient to allow specialization for use in 
constructing a radiation protection material. Particular areas for development in such an 
approach include: 
 Reduction and/or elimination of grain boundaries in solid thin-film coatings 
 Material buildup via atomic layer deposition for near ideal interfacial adhesion 
 Addition of a graded density and composition of nanoparticles and functional groups 
engineered to increase H content and provide net capture cross sections for relevant 
classes of particles. 
 Polymer composite encapsulation loaded with H-infused nanostructured carbon 
allotropes  
 Additively manufactured wearable and graded polymers and metals that act both as 
a tuned radiation shielding material and a scaffold for additional H-infused 
materials. 
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The benefits of a tunable nanomaterial approach infused into the bulk radiation 
protection allow for matching specific regions of an astronauts’ space suit to the 
shielding performance required for various parts of the body.  Integration of this 
approach with an additive manufacturing (AM) fabrication method may allow for 
increased flexibility of typically rigid materials and an ability to customize an AM 
manufactured suit based on astronauts’ specific measurements for better fit and 
radiation protection. Some other benefits of this overall approach include: 
 Structurally flexible nano-scale options 
 Wide range of possibilities for material design 
 High strength to weight ratio 
 Ability to infuse existing polymer based radiation shielding materials with 
nanomaterials 
 Ability to infuse nanomaterials (e.g. carbon and boron nitride nanotubes) with high Z 
materials 
 AM provides capability to fabricate high or low Z shielding material as a wearable 
scaffolding for integration with other shielding materials to provide a tailored 
solution 
By designing materials at the nano-scale, e.g., through graded Z materials, multi-
layering, infused matrices and reinforces polymers, the performance characteristics of a 
component can be aligned with anticipated high energy proton and heavy ion radiation 
environments and thus optimize the protection provided to the astronauts. 
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3.4. Material Testing 
 
3.4.1. Introduction 
 
Charged particles interact with matter by different physical mechanisms than most 
common types of ground radiation. From a physics standpoint, the processes of interest 
are the attenuation of the primary radiation (mostly be electronic processes) and 
generation of secondary radiation by nuclear interaction.  Low atomic number materials 
(especially hydrogen) provide best shielding properties for space radiation.  Practical 
constraints however may limit use of ideal atomic species shielding material.  Such 
constraints include safety considerations for space applications (flammability, toxicity, 
out-gassing, contamination, etc.) as well as geometrical constraints (i.e., materials have 
to be of sufficiently high density to provide significant radiation protection within the 
given spatial envelope).  Overall, defining the best shielding material combination is a 
balancing act of atomic properties, which favor low-Z materials, and macroscopic 
properties, especially density, which tend to favor higher-Z materials. Radiation 
modeling by deterministic or stochastic transport codes is the first method to 
benchmark radiation shielding materials and material combinations.  However 
experimental validation of the analytic results is considered the ultimate evidence of 
shielding efficacy.  Radiation measurements of interest include verification of material 
stopping power.  For low-Z materials and energies characteristic to space radiation, this 
process is mostly due to electronic interaction. The contribution of nuclear interactions 
increase with increasing Z in the target materials, and consequently the amount of 
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secondary radiation.  Measurements of primary environment attenuation can be 
performed using commonly available detectors.  Characterization of the secondary 
radiation environment is more difficult and requires advanced detectors. 
3.4.2. Proton Beam Experiment 
 
The radiation measurements performed to date focused on primary environment 
attenuation.  They were performed at the Francis S. Burr Proton Therapy Center at the 
Massachusetts General Hospital in Boston, MA, USA.  Detectors used included ionization 
chambers (with discrete Lucite degraders) and a Multi-Leaf Ion Chamber.  The primary 
intent was to develop a methodology to be used later in the program for material / 
material combination benchmarking.  Figure 7 presents measurements performed with 
ionization chamber.  Two material samples of known material compositions were 
irradiated in a 50 MeV proton beam.  Iterative combinations of calibrated Lucite 
samples were used to degrade the beam in sufficient steps to accurately determine the 
residual range of the protons – expressed as the distal 50% of the Bragg peak - after 
passing through each material sample. Measurements were compared with analytic 
predictions, and were found to agree within 2%. The plot represents both ionization 
chamber measurements, and analytically derived stopping power (expressed relative to 
the standard material Lucite) for the two samples of Kevlar and Epoxy, respectively.  
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Figure 7. Results of material sample characterization by proton testing. Mass density normalized 
stopping power is presented relative to that of standard material (Lucite).  Analytic predictions 
shown for a subset of material samples are in very good agreement with measurements thus 
validating the experimental approach. 
 
Figure 8 represents measurement results obtained with a multi leaf ionization chamber 
(MLIC).  The MLIC captures the full residual Bragg curve after the incident beam is 
degraded through the sample.  The nominal beam energy incident on the sample was 69 
MeV.  The sample consisted of a heavy liquid of areal density 3.1 g/cm2 placed inside a 
rectangular container.  A second set of measurements were performed of an identical 
empty container to determine and subtract its contribution.  The measurement results 
indicated the water-equivalent thickness of the liquid sample amounted to 1.9 g/cm2.  
This can be interpreted as a 39% more mass effectiveness of water shielding vs. heavy 
liquid.  This result is consistent with expectations based on the typical heavy liquid 
chemical make-up including high-Z components such as Tungsten. 
These preliminary results provide good confidence that the measurements and 
analytic methods of characterizing materials are understood and will be used to develop 
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a standard benchmarking procedure for radiation properties validation of materials to 
be considered for the vest.  
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Figure 8. Results of material sample characterization by proton testing. Dose depth profiles are 
presented as measured with a multi-leaf ion chamber (MLIC) for a container both empty, and 
filled with a liquid sample of areal density of 3.1 g/cm
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3.4.1. SRIM Testing of Candidate Materials 
 
Several materials of interest for potential use in the AstroRad were investigated using 
SRIM (Ziegler et. al. 2010) in order to benchmark their performance in terms of stopping 
ranges for various energies of incident protons. These materials were selected due to 
their material properties, availability, relatively low generation of secondary radiation, 
and shielding properties. The projected proton ranges shown in Table 4 below serve as 
an indication of the amount of shielding required to stop the primary proton beams. It is 
important to note that this data does not indicate generation of secondary radiation. 
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Table 4. SRIM Projected Ranges through Materials of Interest 
 Proton Ranges (Energies in MeV, ranges in 
mm) 
Material Formula 
Density (g/cc) 
30 MeV 50 MeV 100 MeV 200 MeV 
hydrogenated 
BNNT (boron 
nitride 
nanotubes) 
B12N12H24 2.62 3.49 8.81 30.63 103.34 
cubic boron 
nitride 
BN 3.50 2.92 7.34 25.44 85.64 
boron nitride BN 2.10 4.86 12.23 42.40 142.73 
high density 
polyethylene 
(HDPE) 
C2H4 0.96 8.48 21.43 74.69 252.47 
boron B 2.34 4.49 11.32 39.29 132.43 
aluminum Al 2.70 4.33 10.75 36.49 122.62 
water H2O 1.00 8.69 21.89 76.03 256.19 
cBN 5% filler 
(by mass) in 
HDPE 
BN + C2H4 1.09 7.56 19.12 66.61 225.13 
cBN 10% filler 
(by mass) in 
HDPE 
BN + C2H4 1.21 6.84 17.29 60.24 203.55 
cBN 15% filler 
(by mass) in 
HDPE 
BN + C2H4 1.34 6.26 15.83 55.12 186.22 
cBN 20% filler 
(by mass) in 
HDPE 
BN + C2H4 1.47 5.78 14.60 50.82 171.67 
cBN 25% filler 
(by mass) in 
HDPE 
BN + C2H4 1.60 5.37 13.58 47.25 159.59 
cBN 30% filler 
(by mass) in 
HDPE 
BN + C2H4 1.72 5.03 12.71 44.22 149.32 
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3.5. MCNPX Testing of Candidate Materials 
 
Accessing the generation of secondary radiation resulting from interactions of high 
energy GCR with the potential shielding materials is a more difficult task. Due to the 
high energies of GCR particles, many secondary particles are generated which must be 
tracked, quickly adding up to large amounts of computational time. A preliminary 
investigation has been done using MCNPX with more thorough analysis to follow. 
This simulation geometry consisted of spherical shells surrounding a central sphere of 
ICRU 99 tissue equivalent plastic (A-150) target. An estimate of the intrinsic generic 
Orion shielding of 10.7 g/cm2 was used as an outer shell, 3.96 cm thickness. Directly 
below the Al shell is a shell of 5 cm thickness consisting of the candidate material (one 
per simulation, see Table 4). A set thickness of 5 cm was chosen despite variable density 
of the candidate materials due to the thickness of the AstroRad and not the mass being 
considered the primary constraint. Due to computational limitations, only the 106 
particles were run per simulation. The results from this preliminary study using MCNPX 
should be taken to be relative as a tool to compare the value of these particular 
materials and not as absolute values of shielding capabilities for GCR due to the low 
number of particles and particles types (electrons should be included but were excluded 
for the sake of computational time). The source consisted of 16 GeV oxygen ions omni-
directional incident into the spherical geometry. 1 GeV/nucleon oxygen were chosen as 
a first benchmark in order to allow for future fragmentation comparisons with past work 
comparing PHITS, MCNPX, and HZETRN at this energy (Mansur et. al. 2009). F6 tallies 
tracked the energy deposition to the tissue equivalent target for the following particle 
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types: photon, neutron, deuteron, triton, He-3, alpha, proton, and heavy ions. ICRP 60 
quality factors were used to calculate the dose equivalent per 106 incident particles in 
order to compare the efficacy of these materials (ICRP, 1991). Future, more thorough 
studies are recommended and will be compared to HZETRN results as well. The 
candidate materials and results are shown in Table 5 and the MCNPX input code can be 
found in Appendix VI.   
Table 5. Dose Equivalent (Sv) per 10
6
 Source Particles Passing through Al shielding and 
Candidate Materials 
Material Hydrogenated  
Boron Nitride 
Nanotubes 
(BNNT) 
cubic 
boron 
nitride 
(cBN) 
high density 
polyethylene 
(HDPE) 
Aluminum cBN 30% 
filler (by 
mass) in 
HDPE 
Void 
Formula B12N12H24 BN C2H4 Al BN + 
C2H4 
N/A 
Density 
(g/cc) 
2.62 3.50 0.96 2.70 1.72 0.00 
Heavy 
ion 
3.61E-05 3.63E-05 4.26E-05 4.24E-05 3.91E-05 4.38E-05 
Alpha 2.28E-06 2.21E-06 2.06E-06 1.97E-06 2.19E-06 2.06E-06 
He-3 1.03E-06 1.04E-06 9.77E-07 9.68E-07 1.01E-06 9.69E-07 
Triton 6.54E-08 6.50E-08 6.22E-08 6.22E-08 6.42E-08 6.18E-08 
Dueteron 2.77E-07 2.91E-07 2.67E-07 2.95E-07 2.73E-07 2.53E-07 
Proton 3.19E-06 3.30E-06 2.79E-06 2.92E-06 3.00E-06 2.66E-06 
Neutron 2.07E-07 2.57E-07 1.62E-07 2.20E-07 1.82E-07 1.44E-07 
Photon 1.11E-08 1.25E-08 8.99E-09 1.55E-08 1.02E-08 6.40E-09 
Total 4.32E-05 4.35E-05 4.89E-05 4.89E-05 4.59E-05 4.99E-05 
Max Tally 
Error (%) 
0.94 1.12 1.13 0.98 0.88 1.11 
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Chapter 4. ASTRORAD ENGINEERING METHODOLOGY 
 
4.1. Introduction 
 
In zero gravity, it is expected that the physical thickness of the vest, rather than the total 
mass, will constitute the limiting anthropometric and mobility factor.  Reduction of the 
vest thickness will be researched as potentially accomplished by use of graded shields 
consisting of successive layers of high density, high-Z materials and low density, 
hydrogen-rich compounds.  This approach is commercially used for radiation hardening 
of active electronic components and extension of its applicability will be investigated for 
manned space flight relevant environments.  Radiation shielding efficacy of the 
individual materials and graded shields will be initially pursued analytically using 
deterministic software HZETRN, and refined / confirmed by Monte Carlo radiation 
transport modeling code FLUKA. 
For this study, the integrated radiation modeling can be described as the sum of three 
factors: 
Available shielding = Intrinsic body shielding + Vehicle shielding + vest shielding  
1. Intrinsic Human body shielding:   computerized human models for human male 
and female were created, which are based on the ‘visible human’ from NIH.  The model 
is an 1800-image stack for each, from head to toe which Contains differential density of 
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tissue/bone.  Foci of protection for each organ will be defined, in addition to known foci 
of Pelvic bone marrow.   
For inclusion into the current Lockheed Martin radiation models, which use the Air 
Force Human model, an extrapolation will be done from the NIH model to the AF model.  
Two models are used because the tissue ‘resolution’ of the Air Force Human is not as 
great as the NIH model.   The increased resolution of the NIH model is taken advantage 
of in the determination of the foci, and the simpler AF model is used for the 
computationally intensive radiation transport modeling.   
In this fashion the intrinsic attenuation as a function of position in the body will be 
provided into the existing Lockheed Martin space radiation analysis tools.  Also included 
with the model is meta data that describes each part of the human model (see Appendix 
VII).  The human, including both foci location, intrinsic shielding, and meta-data are 
included in a CAD model of the visible human to represent the attenuation map. 
Because both male and female astronauts will be present in NASA’s missions, both will 
be modeled in the vest design.  Because of different tissue distribution and the different 
location of sensitive reproduction organs, the models will be different.  As vest concepts 
are designed and analyzed, one potential outcome is that each astronaut has a vest 
uniquely designed not just for their external body shape, but for their organ distribution, 
internal geometry, age, and any other sensitivities that are subject-specific.   
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2.  Vest Modeling:  Materials work for the vest will begin with a simplified model.  
To model a sandwich of layers, the equivalent density of the layers will be modeled in 
the transport code as a simplified material.  In particular, water and its thickness will be 
modeled because of its high hydrogen content and well known properties.   
To include LM proprietary nano-materials in the design, the team will first conduct tests 
of candidate shield materials.  From this testing, and from knowledge of the ‘nano-
scopic’ properties of the material, an equivalence function of ‘nano-materials property’ 
to modeled property will be included into the transport model.  For example, the ‘water’ 
equivalent of a nano-material layer may be able to significantly reduce the thickness and 
mass of the vest.   
3. Vehicle Shielding:  In cis-lunar space, the Orion transport capsule will be mated 
to a habitat such as NASA’s Exploration Augmentation Module.  The habitat model will 
be added to the existing high fidelity Orion vehicle model.  The habitat radiation 
protection model is currently under development as part of Lockheed Martin’s ongoing 
studies into cis-lunar exploration architectures.   
The integrated modeling will combine the three factors: intrinsic human body, vest and 
vehicle shielding.  Items such as the position of the human in the vehicle and the 
position of the vest on the human (i.e. coordinate system definition) will be defined for 
different cases during the mission. 
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The requirement that we will judge against will be ALARA, as low as reasonably 
available, with a notional goal of 3% REID.  Cis-lunar environment will be modeled first 
and followed with modeling for a Mars mission.  
4.2. Female Human Model Development and AstroRad Shape Definition 
4.2.1. Computerized Female Phantom Development 
 
The goal was to create a vest like shield that optimizes the use of shielding material to 
specifically protect the ovaries, lungs, stomach, colon, breast glandular tissue and red 
bone marrow present in the iliac bones.  These organs and tissues were selected due to 
their high tissue weighting factors (WT) which is a relative measure of the risk of 
stochastic effects due to radiation exposure.  By primarily focusing protection on these 
tissues, the greatest biological benefit is derived per unit mass of shielding by reducing 
the probability of radiation exposure induced death (REID) according to the calculation 
of effective dose.  It is also hypothesized that by biasing radiation protection towards 
resident stem cell concentrations within these tissues even greater relative biological 
protective benefits are incurred due to the propagation of those stem cells over time. 
Additionally, active bone marrow is known to be of extreme importance in cases of 
acute exposure leading to ARS.   
The Visible Human Data set was employed for this purpose. The Visible Human Project is 
the creation of complete, anatomically detailed, three-dimensional representations of 
the normal male and female human bodies and is run by the U.S. National Library of 
Medicine (NLM). The data set includes transverse CT, MR and cryo-section images of 
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representative male and female cadavers. The male was sectioned at one millimeter 
intervals, the female at one-third of a millimeter intervals. 
This powerful tool allowed us to study the tissues surrounding selected organs and 
measure their thickness and determine their overall radiodensity in order to determine 
tissue attenuation (AT), desired total attenuation (DAT) and required radiation 
attenuation (AR) for protecting selected organs from space-borne radiation in an adult 
female.  The human female was chosen to be explored first due to their relative 
sensitivity to stochastic effects of radiation compared to the human male.    
By studying hundreds of slices of the legs, pelvic and torso areas and complementing 
these studies by CT scans, we have mapped the tissue type and thickness present 
between the foci of protection and radiation entry points for hundreds of thousands of 
points along the external surface of the body around the legs, waist, and torso areas.  
A computerized model of the Visible Human Female was obtained from Professor 
Sergey Makarov of the Worcester Polytechnic Institute in Massachusetts for use in the 
study (Yanamadala, 2015).  For the purposes of this research, this model required 
significant improvements and extensive alterations.  Due to her reproductive organs not 
being representative of a young woman, her ovaries were rebuilt using Rhino 5 software 
to be representative of a young woman according to International Commission on 
Radiation Protection (ICRP) Report 89 (ICRP, 2002).  Her breast glandular tissue, thyroid, 
pancreas, and spleen were also missing from this computerized model so they were 
built using raw image data from the Visible Human project and using data from ICRP 89 
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to ensure anatomical accuracy (ICRP, 2002).  The spinal cord, colon, and small intestine 
all were restructured in order to have better resolution of energy deposition in future 
simulations.  This modified computerized human female phantom originally based on 
the Visible Human Project data was named Golda by the AstroRad team.    
Since the HZETRN radiation transport code requires the designation of dose points 
within the organ and tissue systems in the body to measure effective dose, those also 
had to be assigned within the geometry of the computerized model.  The dose point 
locations for the blood forming organs were distributed according to ICRP 89 active 
bone marrow distribution data.  In a similar fashion, the dose point locations for bone 
surface were also assigned according to ICRP 89 mass distribution (ICRP, 2002).    
Foci of protection were then designated within the body.  These foci of protection are 
designated three-dimensional points centered on the center of mass of stem cell niches 
of each organ targeted for protection by selective shielding.  Using the images from the 
Visible Human Project and information available in biological literature, we located the 
areas within the stomach, colon, lungs, breast glandular tissue, iliac red bone marrow, 
and ovaries which had the highest concentrations of stem cells. ImageJ 3D object 
counter (Schneider et. al. 2012) was used to calculate the center of masses of each of 
these stem cell niches once their 3D volumes were rendered from the original image 
stack provided by the Visible Human Project Dataset (Ackerman et. al. 1995).  For the 
organs with bilateral stem cell niches (lungs, iliac red bone marrow, and ovaries), two 
foci of protection were used; one for each side of the phantom.    
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4.2.2. Creation of Self-Shielding Attenuation Map of Surface 
 
Ray tracing methods were employed using this model in order to measure the thickness 
and radiodensity of the underlying tissue between each foci of protection point and 
every point on the surface of the body.  This ray tracing method calculated the straight-
path distances from each foci of protection to each point on the phantom’s external 
surface while tracking the segment distances through various tissues of varying densities 
(adipose tissue, bone, muscle, skin and organs) (ICRP, 2002).  By multiplying each 
distance segment by the density of the tissue the segment traversed, final values of 
areal density of tissue shielding in units of g/cm2 were determined at each point on the 
surface of the phantom for each of the 15 foci of protection points.  The point cloud 
data was used in combination with the densities from ICRP 89 to perform this 
calculation using Microsoft Excel and a proprietary MATLAB code developed by 
StemRad (MATLAB, 2012).  
For each point along the external surface of the phantom there were now 15 different 
values for areal density of intrinsic body shielding corresponding to each of the 15 foci 
of protection for the stomach, colon, lungs, breast glandular tissue, iliac red bone 
marrow, and ovaries.  The lowest areal density value for each point on the surface was 
used thus ensuring that each that each foci of protection receives the benefits of at least 
that areal density of intrinsic body shielding and not less.  Not only was this a 
conservative approach to calculating the areal density shielding provided by the body, 
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but it was also logical as the lowest areal density value for each point along the surface 
is the one corresponding to the most local foci of protection.   
The points along the external surface of the phantom were then grouped into area 
regions on the phantom by rounding their areal densities to the nearest 1 g/cm2 values.  
This results in the 20 different area regions on the external surface of the phantom 
corresponding to areas which provide from 22 to 3 g/cm2 areal density of tissue 
shielding.  This attenuation map on the body’s surface serves as a map for prioritization 
of shielding materials over the surface for maximum efficiency of protection. It was then 
used to define the thickness of shielding which the vest will provide on different areas of 
the body. The desired shield attenuation (AR) component for each region equals the 
desired total attenuation (DAT) minus the tissue attenuation (AT) component for each 
region.   
Simonsen et al. 1997 shows that beyond areal density of 20 g/cm2 water, the effects of 
additional shielding diminish for GCR spectra at solar minimum (Simonsen et al. 1997).  
This information combined with mass, anthropomorphic and ergonomic constraints 
rendering a PPE device providing areal density beyond 20 g/cm2 unpractical led us to the 
conclusion to provide at least 20 g/cm2 of desired shielding from PPE for space 
applications.   
Therefore, the most self-shielded region requiring additional shielding (19 g/cm2 region) 
has a desired shielding requirement of 1 g/cm2 while the least shielded region (3 g/cm2) 
66 
 
requires 17 g/cm2. Some regions with self-shielding in excess of 20 g/cm2 were included 
in the vest coverage area for the sake of ergonomics/continuity. 
 
Figure 9. Attenuation Map of the Female body showing amount of self-shielding provided by soft 
tissue to organs of high priority for protection 
 
4.2.3. Definition of Variable Thickness Over Surface of Body 
Water and/or polyethylene contained within a wearable vest-like device as the primary 
radiation attenuating material to achieve these desired shielding requirements over the 
surface of the body resulted in a planned surface-topography for a radiation protection 
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device which provides highly efficient protection to the selected organs and tissues from 
space-borne radiation.   
Based on these methods, several CAD models of the shielding design have been 
developed which differ in various constraints (adjustments in maximum thickness and 
mass for example) of the shielding scheme which are due to undergo testing through 
HZETRN simulations to quantify their efficacy in effective dose reduction to the modified 
Visible Human Female computerized phantom (Golda).  Figure 10 illustrates preliminary 
CAD models of the layered, variable thickness vest versions.  
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Figure 10. CAD Design of AstroRad showing variable thickness to optimize use of shielding 
material by prioritizing shielding allocation over the surface taking into account the self-
shielding of the body for most radiosensitive organs, tissues and stem-cell niches. 
 
4.3. Design Concepts Development  
The unique working environment inside a spacecraft and usage scenarios dictate the 
need to meet multiple product requirements simultaneously. The AstroRad must 
minimize bulkiness due to ergonomic and volume constraints. It should allow for 
incorporation of radiation attenuating materials, allow flexibility for the user, and meet 
product requirements for use on-board spacecraft (i.e. flammability, outgassing, etc.). 
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The interface with the human body is also extremely important and breathability and 
heat-retention must also be taken into account. 
A primary constraint is to minimize volume to avoid bulkiness and therefore maximizing 
the density of material components is desirable. However, dense materials (i.e. solids) 
are inherently inflexible. Therefore, developing design concepts which integrate solid 
form radiation attenuating materials into an orientation which provides flexibility and 
comfort to the user is necessary.  
Two design concepts which attempt to address this issue are being investigated. These 
design concepts are designated as the hive and sequins. Each design concept has 
already been manufactured at a coupon level for testing advantageous and 
disadvantages in order to arrive at an optimal configuration for use in the AstroRad. 
Manufacturing the AstroRad using layers of any of these design concepts stacked in the 
variable thickness configuration would create a layout with high areal density while 
incorporating radiation attenuating materials while allowing for user mobility. 
The hive concept consists of a flexible matrix with embedded hexagonal solid pieces. 
The hexagonal solid components include a uniform void allowing for the insertion of 
recycled plastic packaging materials which could be manufactured in-orbit using a mold 
or by 3D printing. The flexible matrix allows for stretching and compression with user 
movement allowing for full range of motion while the inclusion of a high percentage of 
solid structure maximizes areal density and radiation attenuation. 
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Figure 11. Hive Design concept coupon material 
 
 
Figure 12. Hive coupon material backside view with voids for insertion of reprocessed packaging 
material 
         
The sequins design concept uses thin solid pieces attached to a thin, flexible polymer. 
Sheets of this structure can be manufactured and layered to form the needed thickness 
over the surface of the body in creating the AstroRad. The sequins pieces themselves 
could be made of repurposed plastics packaging material aboard the spacecraft. 
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Figure 13. Sequins Design Concept 
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Chapter 5. ASTRORAD SIMULATION RESULTS 
 
Multiple iterative efforts were completed to optimize the design of the vest. A baselined 
approach for the analysis to predict the exposure to the crew without the vest 
leveraging the Orion MPCV as a generic vehicle.  State of the art process involving 
biologically accurate human Anatomical Female model (Golda) along with the generic 
spacecraft shielding.  Radiation transport software was used in conjunction with space 
radiation environment models to predict radiation exposure at organ level.   
The material for the CAD model used from the latest design concept was assigned as 
HDPE, having mass of 57.50 lbs (26.08 kg and 26,880 cm3).  This mass was considered 
based on human engineering expertise available to LM from previous space programs.   
Sector analysis software was used to characterize vest design from a number of 529 
internal body points distributed over the set of organs relevant to space radiation 
protection.  This protection was considered as a supplement to the generic vehicle 
shielding in the baseline. Results shown in table indicate significant improvements in 
radiation protection as indicated by a decrease in effective dose for the design SPE from 
229 mSv to 121 mSv, consistent with a reduction of more than 45% in the risk of 
radiation induced cancer. The analyzed vest showed also significant reductions of 
averaged dose-equivalents to most organs of more than 35%. 
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Figure 14. Latest Analyzed AstroRad Vest Concept 
 
Table 6. Radiation averaged dose-equivalents to specific organs using Golda Female Model 
Golda Human Model 
  Control AstroRad 
Organ Dose(mSv) Dose(mSv) 
BFO 234.20 134.38 
Bladder 152.28 102.05 
Bones 417.91 328.16 
Brain 113.25 110.59 
Breast 707.22 181.70 
Colon 184.27 94.19 
Esophagus 165.41 102.47 
Muscle 492.92 327.72 
Skin      1160.98 720.05 
Eyes 685.56 664.66 
Kidney 176.19 85.03 
Liver 138.45 70.27 
Lungs 202.58 104.16 
Ovaries 145.98 88.17 
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Pancreas 109.41 61.59 
Spinal Cord 213.65 120.73 
Spleen 257.70 104.85 
Stomach 142.73 73.024 
Thyroid 413.48 249.25 
Uterus 164.35 91.93 
Intestines 210.55 98.64 
Effective 
Dose(mSv) 228.95 121.35 
 
 
Figure 15. Cross Section of the Human Anatomical Female Model (Golda) 
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Chapter 6. FUTURE TESTING 
 
6.1. Validation of Radiation Shielding Effectivity 
 
Radiation testing is in relevant radiation environments is the ultimate confirmation 
shielding properties of the AstroRad design.  Envisioned measurements to validate 
radiation shielding benefit of the AstroRad vest includes both ground- and flight tests.  
The NASA Space Radiation Laboratory (NSRL) facility at the Brookhaven National 
Laboratory (BNL) is a state-of-the art facility capable of providing proton beam of energy 
up to 2.5 GeV and various heavy ion beam of energies up to 1 GeV/u.  Such high beam 
energies allow performance of fragmentation studies relevant for characterization of 
the secondary radiation generated by interaction of GCR (and to a lesser degree, the 
high energy spectral component of SPE) with matter.  An effort is being pursued to fly 
AstroRad on the Orion Exploration Mission 1 (EM-1) flight as constituent of a science 
payload.  EM-1 is an unmanned test flight in cis-lunar space.  The science experiment 
under consideration consists of two anthropomorphic radiation phantoms positioned 
inside the Orion Crew Module habitable space, and retrofitted with dosimeters at 
various external (skin) and internal (organ point) locations.  The phantom materials are 
designed to be tissue equivalent for purposes of radiation interactions; the phantoms 
also include human skeleton (bones) and have internal density characteristic of the 
various organs (e.g., lungs).  This in turn renders the dose measurements representative 
of the radiation exposure of the real astronaut crew.   One radiation phantom is planned 
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to be fitted with the AstroRad radiation vest.  Placement of dosimeters with respect to 
the vest will allow determination of vest effectiveness in reducing radiation exposure.  
The radiation experiment on the Orion EM-1 mission is considered to add significant 
science value to the mission.  Space radiation measurements using tissue equivalent 
phantoms have been of interest to the space radiation community and have resulted in 
multiple dosimetry inter-comparison campaigns aboard the International Space Station 
(ISS).  Orion EM-1 represents a unique opportunity to augment the ISS data with 
measurements of the significantly different (harsher) GCR environment encountered 
outside Earth’s magnetosphere, van Allen belt transit (depending upon trajectory) and 
potentially solar protons.  In addition, these data will be representative of the internal 
environment of NASA’s next generation Exploration spacecraft that will take human 
astronauts to deep space destinations such as the Moon and Mars.           
6.2. Future Spacecraft Mockup Facility Testing  
 
In order to design the AstroRad for maximal usability inside the Orion spacecraft and 
other habitats, this study will use an AstroRad conceptual prototype in a variety of space 
vehicle simulators. The conceptual prototype is an early prototype which is specifically 
designed to have the correct dimensions of the final AstroRad product, but made of 
non-optimal radiation attenuation materials with low density. This enables the AstroRad 
conceptual prototype to be worn comfortably on Earth as opposed to the final product 
which will be used in microgravity conditions. Therefore, the conceptual prototype is 
intended to be used to assess the volumetric and human-interface constraints inside 
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spacecraft environments. This testing will provide valuable feedback, validation and 
verification of the AstroRad approach to astronauts’ personal radiation shielding. During 
the upcoming environmental tests, the goal is to evaluate the AstroRad vest ability to 
allow freedom of movement and convenience while providing radiation protection to an 
astronaut. 
 
Figure 16. AstroRad Conceptual Prototype for Human Interface Testing at NASA Johnson 
Space Center Building 9 
 
The test procedures are designed to simulate the movements inside space vehicles or 
habitats in which current and future deep space missions are planned to take place. In 
the course of the test process, a model wearing a conceptual prototype will test and 
verify the suitability of the conceptual prototype in executing defined tasks, simulating 
astronaut's activity during space mission. Among the exercised activities: 
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 Testing different stowage options for the AstroRad  
 Verifying ease of donning/removing 
 Checking for issues that may arise while being in a habitat; going through 
passages, exercising etc.   
The tests will be conducted in three different variants, correlating with the three 
thickness levels of the vest. 
In order to quantify the results, subjective rating criteria is defined for system 
performance (How the vest is suitable for astronaut use in spacecraft). The model will 
be female astronaut evaluator and the tests will take place in NASA facility located in 
building 9 in JSC.  
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Chapter 7. DISCUSSION  
 
In Human space flight, protecting the life and health of the astronaut is at once the most 
challenging and the most important part of any system design.  Long duration missions 
outside the Earth’s magnetic field pose a brand-new challenge.  Similarly, while a great 
deal of research into the biological effects of radiation has been conducted, engineered 
countermeasure solutions are few in number.  The AstroRad vest, with its unique blend 
of ergonomics and protection, represents an important step towards long term 
astronaut survival as we explore the solar system.   
The work leading to AstroRad represents a unique combination of entrepreneurial 
talent from a new participant in the Human Space Flight enterprise with the established 
and deep expertise of a major player in the industry.  The StemRad staff has developed a 
human model for this analysis which included the latest knowledge of stem cell ‘niches,’ 
a feature not contained in previously used models such as the Computer Aided Female 
(CAF).  Including the resulting ‘Golda’ model in LM space radiation analysis provides 
unprecedented fidelity and visibility to radiation transport to stem cells.  Through 
combination of Lockheed Martin and StemRad, the concepts proven in selective cell 
protection used on earth can be effectively applied in the space environment.   
Material selection has been performed in two areas, the use of novel manufacturing 
techniques on a familiar material, and the evaluation of nano-materials to augment 
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high-hydrogen polyethylene.  A positive analysis result is that an easy-to-make vest 
provides substantial protection from Solar Particle events.  The AstroRad team is 
confident enough in the results of an all-polyethelene design that we have performed 
vest donning and doffing tests in an Orion and ISS mockup.  Should nano-materials 
prove effective, they will only decrease the size of the garment and add to the 
operational efficacy. Further material testing is planned including irradiation 
experiments at NSRL and simulations using PHITS, HZETRN, and MCNP. 
Because astronaut confinement in a storm shelter for the duration of these events may 
be operationally difficult, the use of a vest may be an important augmentation to the 
crew equipment.  In some cases, the vest could allow safe resumption of at least 
operations even if the storm continues.  As the team pursues design modifications, we 
will interact with the Lockheed Martin NextSTEP habitat design team, exploring how an 
AstroRad vest works with scenarios in the Lockheed Martin Habitat prototype.  
There is significant future work to be done, and the team is being paced by the goal of 
flying a vest on a future Orion mission.  Knowledge gained from ergonomic activity 
testing and future material developments, will be included in future prototypes, leading 
up to a flight product.  During these design iterations, the LM/StemRad team will 
continually consult with important stakeholders in NASA and the academic community 
to ensure a valuable product results to protect astronaut health on the challenging 
Journey to Mars.  
 
81 
 
 
REFERENCES 
 
1. Schimmerling, Walter. "The Space Radiation Environment: An Introduction". The 
Health Risks of Extraterrestrial Environments. Universities Space Research 
Association Division of Space Life Sciences. Retrieved 2011-12-05. 
2. Fujita, S., H. Kato, and W.J. Schull, The LD50 associated with exposure to the atomic 
bombing of Hiroshima and Nagasaki. J Radiat Res, 1991. 32 Suppl: p. 154-61.  
3. CDC. Acute Radiation Syndrome: Fact Sheet for Physicians. Accessed March 23, 2012; 
Available from: http://www.bt.cdc.gov/radiation/ars.asp. 
4. F. A. Cucinotta, L. Chappell, M. Y. Kim, "Space radiation cancer risk projections 
and uncertainties – 2012, NASA/TP - 2013 - 217375 (2013). 
5. NCRP Report #132, Radiation Protection Guidance for Activities in Low-Earth 
Orbit, R. J. M. Fry, Chairman, National Council on Radiation Protection and 
Measurements, Bethesda, MD (2000). 
6. Davis, A.J., Mewaldt, R.A., Binns, W.R., et al. The evolution of galactic cosmic ray 
element spectra from solar minimum to solar maximum:ACE measurements, in: 
Proceedings of the 27th ICRC, Hamburg, vol.10, pp. 3971–3974, 2001. 
7. Kim, M.Y., Hayat, M.J., Ferveson, A.H. and Cucinotta, F. A. Prediction of frequency 
and exposure level of solarparticle events. Health Phys 97, 68-81 (2009). 
8. Usoskin, I.G. & Kovaltsov, G.A. Occurrence of extreme solar particle events: 
Assessment from historical proxy data. The Astrophysical Journal 757, 92 (2012). 
9. R. A. Mewaldt,Space Science Reviews,DOI: 10.1007/s 11214-006-9091-0 (2006).  
82 
 
10.  Radiation  Risk  acceptability  and  limitations.  Cucinotta F. 
https://three.jsc.nasa.gov/articles/AstronautRadLimitsFC.pdf.  Date  posted:  12-
21-2010. 
11. Cucinotta,  F.A.,  Kim,  M.Y.  and  Ren,  L.,  “Managing   Lunar  and  Mars  Mission  
Radiation  Risks  Part  I:  Cancer   Risks,    Uncertainties    and    Shielding    
Effectiveness,”     NASA/TP-2005-213164. 
12. H. Bethe und J. Ashkin in "Experimental Nuclear Physics, ed. E. Segré, J. Wiley, New York, 
1953, p. 253. 
13. Martin, James E (2008). Physics for Radiation Protection: A Handbook. pp. 660–661. 
ISBN 978-3-527-61880-4. 
14. Zettl, Alex; Cohen, Marvin (2010). "The physics of boron nitride nanotubes". 
Physics Today. 63 (11): 34–38. 
15. James F. Ziegler, M.D. Ziegler, J.P. Biersack, SRIM – The stopping and range of ions 
in matter (2010), Nuclear Instruments and Methods in Physics Research Section 
B: Beam Interactions with Materials and Atoms, Volume 268, Issues 11–12, June 
2010, Pages 1818-1823, ISSN 0168-583X, 
http://dx.doi.org/10.1016/j.nimb.2010.02.091. 
16. L. Mansur, Y. Charara, S. Guetersloh, I. Remec, L. Townsend. Fragmentation 
calculations for energetic ions in candidate space radiation shielding materials  
Nuclear Technology, vol. 166, p. 263, 2009.  
83 
 
17. International Commission on Radiological Protection (1991). Publication 60: 
Recommendations of the International Commission on Radiological Protection, 
Annals of the ICRP 21(1–3)Oxford: Pergamon Press.  
18. J. Yanamadala, "New VHP-Female v. 2.0 Full-Body Computational Phantom and 
Its Performance Metrics Using FEM Simulator ANSYS HFSS", Proc. IEEE EMBC 
2015. 
19. ICRP, 2002. Basic Anatomical and Physiological Data for Use in Radiological Protection 
Reference Values. ICRP Publication 89. Ann. ICRP 32 (3-4). 
20. Schneider, C. A.; Rasband, W. S. & Eliceiri, K. W. (2012), "NIH Image to ImageJ: 25 
years of image analysis", Nature methods 9(7): 671-675, PMID 22930834 (on Google 
Scholar). 
21. MATLAB and Statistics Toolbox Release 2012b, The MathWorks, Inc., Natick, 
Massachusetts, United States. 
22. Ackerman, M.J., et al., The Visible Human data set: an image resource for 
anatomical visualization. Medinfo, 1995. 8 Pt 2: p. 1195-8. 
23. Simonsen, L. C., (1997) "Analysis of Lunar And Mars Habitation Modules for the 
Space Exploration Initiative (SEI)," in "Shielding Strategies for Human Space 
Exploration," Edited by J. W. Wilson, J. Miller, A. Konradi, and F. A. Cucinotta. 
NASA Conference Publication 3360. NASA3360.pdf 
 
 
 
 
 
 
  
84 
 
Appendix I: MCNP Input file 360 Gamma PNNL Source Recreation 
360 gamma belt   
c this version with legs, head, arms, feet, intestines, ovaries 
c this version with ORNL pelvic anatomy modified 
c this version has legs! 
c this version has version of belt in circular geometry 
c ORNL pelvis and lower spine also included here 
c the ORNL anatomy has been subdivided into many smaller cells for better res.  
c this version teflon omitted 
c 
************************************************************************
****** 
1 3 -7.88 (1 -2):(44 -45 -194 195) imp:p=1 $inner stainless steel 
c 2 2 -2.2 (2 -3):(45 -46 -196 197) imp:p=1 $teflon 1 
3 1 -11.34 (3 -4):(46 -47 -196 197) imp:p=1 $lead 1 
c 4 2 -2.2 (4 -5):(47 -48 -198 199) imp:p=1 $teflon 2 
5 1 -11.34 (5 -6):(48 -49 -198 199) imp:p=1 $lead 2 
c 6 100 -1 (6 -7):(49 -50 68) imp:p=1 $teflon 3 
c 6 2 -2.2 (6 -7 26 27):(6 -7 -26 -27):(6 -7 -26 27):(49 -50 -200 201) imp:p=1   
c teflon 3 
c 7 100 -1 (7 -8):(50 -51 68) imp:p=1 $lead 3 
7 1 -11.34 (7 -8 26 27):(7 -8 -26 -27):(7 -8 -26 27):(50 -51 -200 201) imp:p=1  
c lead 3 
c 8 2 -2.2 (8 -9 28 29):(8 -9 -28 -29):(8 -9 -28 29):(51 -52 -202 203) imp:p=1  
c teflon 4 
9 1 -11.34 (9 -10 28 29):(9 -10 -28 -29):(9 -10 -28 29):(52 -53 -202 203)  
     imp:p=1 $ lead 4 
c 10 2 -2.2 (10 -11 30 31):(10 -11 -30 -31):(10 -11 -30 31):(53 -54 -204 205)  
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     imp:p=1  
c teflon 5 
11 1 -11.34 (11 -12 30 31):(11 -12 -30 -31):(11 -12 -30 31):(54 -55 -204 205)  
     imp:p=1  
c lead 5 
c 12 2 -2.2 (12 -13 32 33):(12 -13 -32 -33):(12 -13 -32 33):(55 -56 -206 207)  
     imp:p=1  
c teflon 6 
13 1 -11.34 (13 -14 32 33):(13 -14 -32 -33):(13 -14 -32 33):(56 -57 -206 207)  
     imp:p=1  
c lead 6 
c 14 2 -2.2 (14 -15 34 35):(14 -15 -34 -35):(14 -15 -34 35):(57 -58 -208 209)  
     imp:p=1  
c teflon 7 
15 1 -11.34 (15 -16 34 35):(15 -16 -34 -35):(15 -16 -34 35):(58 -59 -208 209)  
     imp:p=1  
c lead 7 
c 16 2 -2.2 (16 -17 36 37):(16 -17 -36 -37):(16 -17 -36 37):(59 -60 -210 211)  
     imp:p=1  
c teflon 8 
17 1 -11.34 (17 -69 36 37):(17 -69 -36 -37):(17 -69 -36 37):(60 -61 -210 211)  
     imp:p=1  
c lead 8 
c 18 2 -2.2 (18 -19 -38 39):(62 -63 -212 213) imp:p=1 $teflon 9 
19 1 -11.34 (19 -70 -38 39):(63 -64 -212 213) imp:p=1 $lead 9 
20 1 -11.34 20 -71 -40 41 imp:p=1 $lead 10 
21 1 -11.34 21 -22 -42 43 imp:p=1 $lead 11 
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c 22 2 -2.2 (23 -24):(65 -66 -214 215) imp:p=1 $outer teflon 
23 3 -7.88 (24 -25):(66 -67 -214 215) imp:p=1 $outer stainless steel 
c overlap cells below 
24 3 -7.88 -22 91 81 -82 imp:p=1 $ss1 overlap 
c 25 2 -2.2 -91 92 81 -82 imp:p=1 $teflon 1 overlap 
26 1 -11.34 -92 93 81 -82 imp:p=1 $Pb1 overlap 
c 27 2 -2.2 -93 94 81 -82 imp:p=1 $teflon 2 overlap 
28 1 -11.34 -94 95 81 -82 imp:p=1 $Pb2 overlap 
c 29 100 -1 -95 96 83 -84 imp:p=1 $teflon 3 overlap 
c 30 1 -11.34 -96 97 83 -84 imp:p=1 $Pb3 overlap 
c 31 2 -2.2 -95 98 81 -82 imp:p=1 $teflon outer overlap 
32 3 -7.88 -98 99 81 -82 imp:p=1 $ss outer overlap 
222 4 -0.001225 (-555 804 805 806 807 808 809 810 811 812 813 814 818)  
     #1#9#11#13#15#17#19#20#21#23#24#32#3#5#7#26#28 imp:p=1 $AIR 
333 0 555 imp:p=0 
c anatomy cells 
below*********************************************************** 
c bottom part of pelvis first 
************************************************** 
c 700 6 -1.40 (-704 705 121 -122 101 -102) imp:p=1 vol=1 
c 701 6 -1.40 (-704 705 122 -123 101 -102) imp:p=1 vol=1 
c 702 6 -1.40 (-704 705 123 -124 101 -102) imp:p=1 vol=1 
c 703 6 -1.40 (-704 705 124 -125 101 -102) imp:p=1 vol=1 
c 
************************************************************************
****** 
c 704 6 -1.40 (-704 705 121 -122 102 -103) imp:p=1 vol=1 
c 705 6 -1.40 (-704 705 122 -123 102 -103) imp:p=1 vol=1 
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c 706 6 -1.40 (-704 705 123 -124 102 -103) imp:p=1 vol=1 
c 707 6 -1.40 (-704 705 124 -125 102 -103) imp:p=1 vol=1 
c 
************************************************************************
****** 
c 708 6 -1.40 (-704 705 121 -122 103 -104) imp:p=1 vol=1 
c 709 6 -1.40 (-704 705 122 -123 103 -104) imp:p=1 vol=1 
c 710 6 -1.40 (-704 705 123 -124 103 -104) imp:p=1 vol=1 
c 711 6 -1.40 (-704 705 124 -125 103 -104) imp:p=1 vol=1 
c 
************************************************************************
****** 
c 712 6 -1.40 (-704 705 121 -122 104 -105) imp:p=1 vol=1 
c 713 6 -1.40 (-704 705 122 -123 104 -105) imp:p=1 vol=1 
c 714 6 -1.40 (-704 705 123 -124 104 -105) imp:p=1 vol=1 
c 715 6 -1.40 (-704 705 124 -125 104 -105) imp:p=1 vol=1 
c 
************************************************************************
****** 
c 716 6 -1.40 (-704 705 121 -122 105 -106) imp:p=1 vol=1 
c 717 6 -1.40 (-704 705 122 -123 105 -106) imp:p=1 vol=1 
c 718 6 -1.40 (-704 705 123 -124 105 -106) imp:p=1 vol=1 
c 719 6 -1.40 (-704 705 124 -125 105 -106) imp:p=1 vol=1 
c 
************************************************************************
****** 
720 6 -1.40 (-704 705 121 -122 106 -107) imp:p=1 vol=1 
721 6 -1.40 (-704 705 122 -123 106 -107) imp:p=1 vol=1 
722 6 -1.40 (-704 705 123 -124 106 -107) imp:p=1 vol=1 
723 6 -1.40 (-704 705 124 -125 106 -107) imp:p=1 vol=1 
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c 
************************************************************************
****** 
724 6 -1.40 (-704 705 121 -122 107 -108) imp:p=1 vol=1 
725 6 -1.40 (-704 705 122 -123 107 -108) imp:p=1 vol=1 
726 6 -1.40 (-704 705 123 -124 107 -108) imp:p=1 vol=1 
727 6 -1.40 (-704 705 124 -125 107 -108) imp:p=1 vol=1 
c 
************************************************************************
****** 
c ********Top part of pelvis 
below********************************************** 
750 6 -1.40 (-704 705 121 -122 108 -109) imp:p=1 vol=1 
751 6 -1.40 (-704 705 122 -123 108 -109) imp:p=1 vol=1 
752 6 -1.40 (-704 705 123 -124 108 -109) imp:p=1 vol=1 
753 6 -1.40 (-704 705 124 -125 108 -109) imp:p=1 vol=1 
754 6 -1.40 (-704 705 125 -127 108 -109) imp:p=1 vol=1 
755 6 -1.40 (-704 705 127 108 -109) imp:p=1 vol=1 
c 
************************************************************************
****** 
756 6 -1.40 (-704 705 121 -122 109 -110) imp:p=1 vol=1 
757 6 -1.40 (-704 705 122 -123 109 -110) imp:p=1 vol=1 
758 6 -1.40 (-704 705 123 -124 109 -110) imp:p=1 vol=1 
759 6 -1.40 (-704 705 124 -125 109 -110) imp:p=1 vol=1 
760 6 -1.40 (-704 705 125 -127 109 -110) imp:p=1 vol=1 
761 6 -1.40 (-704 705 127 109 -110) imp:p=1 vol=1 
c 
************************************************************************
****** 
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762 6 -1.40 (-704 705 121 -122 110 -111) imp:p=1 vol=1 
763 6 -1.40 (-704 705 122 -123 110 -111) imp:p=1 vol=1 
764 6 -1.40 (-704 705 123 -124 110 -111) imp:p=1 vol=1 
765 6 -1.40 (-704 705 124 -125 110 -111) imp:p=1 vol=1 
766 6 -1.40 (-704 705 125 -127 110 -111) imp:p=1 vol=1 
767 6 -1.40 (-704 705 127 110 -111) imp:p=1 vol=1 
c 
************************************************************************
****** 
768 6 -1.40 (-704 705 121 -122 111 -112) imp:p=1 vol=1 
769 6 -1.40 (-704 705 122 -123 111 -112) imp:p=1 vol=1 
770 6 -1.40 (-704 705 123 -124 111 -112) imp:p=1 vol=1 
771 6 -1.40 (-704 705 124 -125 111 -112) imp:p=1 vol=1 
772 6 -1.40 (-704 705 125 -127 111 -112) imp:p=1 vol=1 
773 6 -1.40 (-704 705 127 111 -112) imp:p=1 vol=1 
c 
************************************************************************
****** 
c lumbar vertebrae 
800 6 -1.40 112 -113 -802 imp:p=1 vol=1 $L5  
801 6 -1.40 114 -115 -802 imp:p=1 vol=1 $L4  
802 6 -1.40 116 -117 -802 imp:p=1 vol=1 $L3  
803 6 -1.40 118 -119 -802 imp:p=1 vol=1 $L2  
804 6 -1.40 120 -126 -802 imp:p=1 vol=1 $L1  
c torso 
805 7 -1.129 -804#720#721#722#723#724#725#726 
     #727#750#751#752#753#754#755#756#757#758#759#760#761#762#763 
     #764#765#766#767#768#769#770#771#772#773#800#801#802#803#804 
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     #816#817#818 819 imp:p=1  
806 7 -1.129 -805 imp:p=1 $left leg 
807 7 -1.129 -806 imp:p=1 $right leg 
808 7 -1.129 -807 imp:p=1 $left leg 
809 7 -1.129 -808 imp:p=1 $right leg 
810 7 -1.129 -809#811 imp:p=1 $head  
811 7 -1.129 -810 imp:p=1 $neck 
812 7 -1.129 -811 imp:p=1 $right foot  
813 7 -1.129 -812 imp:p=1 $left foot 
814 7 -1.129 -813 804 imp:p=1 $left arm 
815 7 -1.129 -814 804 imp:p=1 $right arm 
816 7 -1.129 -815 imp:p=1 $left ovary 
817 7 -1.129 -816 imp:p=1 $right ovary 
818 7 -1.129 -817 imp:p=1 $large and small intestine 
819 8 -2.3 -818 imp:p=1 $concrete slab 
820 7 -1.129 -819 820 imp:p=1 vol=132.9 $stomach wall 
821 7 -1.129 -820 imp:p=1 vol=1 $stomach contents 
c 
************************************************************************
****** 
 
c *********Surface 
Cards******************************************************** 
1 rcc 0 0 -4 0 0 13 16.230 $inner bound of ss1 
2 rcc 0 0 -4 0 0 13 16.270 $inner bound of teflon1 
3 rcc 0 0 -4 0 0 13 16.282 $inner bound of Pb1 
4 rcc 0 0 -4 0 0 13 16.382 $inner bound of teflon2  
5 rcc 0 0 -4 0 0 13 16.394 $inner bound of Pb2  
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6 rcc 0 0 -4 0 0 13 16.494 $inner bound of teflon3 
7 rcc 0 0 -4 0 0 13 16.506 $inner bound of Pb3  
8 rcc 0 0 -4 0 0 13 16.606 $inner bound of teflon4  
9 rcc 0 0 -4 0 0 13 16.618 $inner bound of Pb4 
10 rcc 0 0 -4 0 0 13 16.718 $inner bound of teflon5  
11 rcc 0 0 -4 0 0 13 16.730 $inner bound of Pb5  
12 rcc 0 0 -4 0 0 13 16.830 $inner bound of teflon6 
13 rcc 0 0 -4 0 0 13 16.842 $inner bound of Pb6 
14 rcc 0 0 -4 0 0 13 16.942 $inner bound of teflon7 
15 rcc 0 0 -4 0 0 13 16.954 $inner bound of Pb7 
16 rcc 0 0 -4 0 0 13 17.054 $inner bound of teflon8 
17 rcc 0 0 -4 0 0 13 17.066 $inner bound of Pb8 
69 rcc 0 0 -4 0 0 13 17.166 $outer bound of Pb8  
18 rcc 0 0 -3 0 0 12 17.166 $inner bound of teflon9 
19 rcc 0 0 -3 0 0 12 17.178 $inner bound of Pb9  
70 rcc 0 0 -3 0 0 12 17.278 $outer bound of Pb9 
20 rcc 0 0 -7.25 0 0 16.25 17.278 $inner bound of Pb10  
71 rcc 0 0 -7.25 0 0 16.25 17.378 $outer bound of Pb10  
21 rcc 0 0 0 0 0 9 17.378 $inner bound of Pb11 
22 rcc 0 0 0 0 0 9 17.478 $outer bound of Pb11  
23 rcc 0 0 -4 0 0 13 17.490 $inner bound of teflonOuter  
24 rcc 0 0 -4 0 0 13 17.530 $inner bound of ss2 
25 rcc 0 0 -4 0 0 13 17.570 $outer bound of ss2 
555 rcc 0 0 -131 0 0 271.77 101 $system boundary 
26 p -36.9338 -9 0 0 $angular bound for cells 6 and 7 
27 p -36.9338 9 0 0 $angular bound for cells 6 and 7 
28 p -13.2309 -9 0 0 $angular bound for cells 8 and 9 
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29 p -13.2309 9 0 0 $angular bound for cells 8 and 9 
30 p -10.9237 -9 0 0 $angular bound for cells 10 and 11 
31 p -10.9237 9 0 0 $angular bound for cells 10 and 11 
32 p -8.0809 -9 0 0 $angular bound for cells 12 and 13 
33 p -8.0809 9 0 0 $angular bound for cells 12 and 13 
34 p -6.1357 -9 0 0 $angular bound for cells 14 and 15 
35 p -6.1357 9 0 0 $angular bound for cells 14 and 15 
36 p -0.3758 -9 0 0 $angular bound for cells 16 and 17 
37 p -0.3758 9 0 0 $angular bound for cells 16 and 17 
38 p 3.2592 -9 0 0 $angular bound for cells 18 and 19 
39 p 3.2592 9 0 0 $angular bound for cells 18 and 19 
40 p 10.1900 -9 0 0 $angular bound for cells 20 
41 p 10.1900 9 0 0 $angular bound for cells 20 
42 p 17.3030 -9 0 0 $angular bound for cells 21 
43 p 17.3030 9 0 0 $angular bound for cells 21 
c bounds for lower part of belt layers below 
44 rcc 0 0 -9 0 0 5 16.230 $inner bound of ss1 lower 
45 rcc 0 0 -9 0 0 5 16.270 $inner bound of teflon1 lower 
46 rcc 0 0 -9 0 0 5 16.282 $inner bound of Pb1 lower 
47 rcc 0 0 -9 0 0 5 16.382 $inner bound of teflon2 lower 
48 rcc 0 0 -9 0 0 5 16.394 $inner bound of Pb2 lower 
49 rcc 0 0 -9 0 0 5 16.494 $inner bound of teflon3 lower 
50 rcc 0 0 -9 0 0 5 16.506 $inner bound of Pb3 lower 
51 rcc 0 0 -9 0 0 5 16.606 $inner bound of teflon4 lower 
52 rcc 0 0 -9 0 0 5 16.618 $inner bound of Pb4 lower 
53 rcc 0 0 -9 0 0 5 16.718 $inner bound of teflon5 lower 
54 rcc 0 0 -9 0 0 5 16.730 $inner bound of Pb5 lower 
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55 rcc 0 0 -9 0 0 5 16.830 $inner bound of teflon6 lower 
56 rcc 0 0 -9 0 0 5 16.842 $inner bound of Pb6 lower 
57 rcc 0 0 -9 0 0 5 16.942 $inner bound of teflon7 lower 
58 rcc 0 0 -9 0 0 5 16.954 $inner bound of Pb7 lower 
59 rcc 0 0 -9 0 0 5 17.054 $inner bound of teflon8 lower 
60 rcc 0 0 -9 0 0 5 17.066 $inner bound of Pb8 lower 
61 rcc 0 0 -9 0 0 5 17.166 $outer bound of Pb8 lower 
62 rcc 0 0 -9 0 0 6 17.166 $inner bound of teflon9 lower 
63 rcc 0 0 -9 0 0 6 17.178 $inner bound of Pb9 lower 
64 rcc 0 0 -9 0 0 6 17.278 $outer bound of Pb9 lower  
65 rcc 0 0 -9 0 0 5 17.490 $inner bound of teflonOuter lower 
66 rcc 0 0 -9 0 0 5 17.530 $inner bound of ss2 lower 
67 rcc 0 0 -9 0 0 5 17.570 $outer bound of ss2 lower 
68 py 0 $ang. boundary for 180 deg lower belt regions lower 
c note: 69, 70 & 71 surface numbers already taken 
c next lines for overlap region surfaces 
81 p 38.5448 -9 0 0 $angular bound all 8cm overlaps 
82 p 38.5448 9 0 0 $angular bound all 8cm overlaps 
83 p 47.31758 -9 0 0 $angular bound tef 3 & pb 3 
84 p 47.31758 9 0 0 $angular bound tef 3 & pb 3 
91 rcc 0 0 -4 0 0 13 17.438 $inner bound of ss1 over. 
92 rcc 0 0 -4 0 0 13 17.426 $inner bound of teflon1 over. 
93 rcc 0 0 -4 0 0 13 17.326 $inner bound of Pb1 over. 
94 rcc 0 0 -4 0 0 13 17.314 $inner bound of teflon2 over. 
95 rcc 0 0 -4 0 0 13 17.214 $inner bound of Pb2 over. 
96 rcc 0 0 -4 0 0 13 17.202 $inner bound of teflon3 over. 
97 rcc 0 0 -4 0 0 13 17.102 $inner bound of Pb3 over. 
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98 rcc 0 0 -4 0 0 13 17.202 $inner bound of teflon outer 
99 rcc 0 0 -4 0 0 13 17.162 $inner bound of ss2 over. 
c 194-215 are ang. bounds for the lower region 
194 p 1.6794 -9 0 0 $angular bound for cell 1  
195 p 1.6794 9 0 0 $angular bound for cell 1  
196 p 1.7111 -9 0 0 $angular bound for cells 2 and 3 
197 p 1.7111 9 0 0 $angular bound for cells 2 and 3 
198 p 1.7994 -9 0 0 $angular bound for cells 4 and 5 
199 p 1.7994 9 0 0 $angular bound for cells 4 and 5 
200 p 1.8869 -9 0 0 $angular bound for cells 6 and 7 
201 p 1.8869 9 0 0 $angular bound for cells 6 and 7 
202 p 1.9735 -9 0 0 $angular bound for cells 8 and 9 
203 p 1.9735 9 0 0 $angular bound for cells 8 and 9 
204 p 2.0593 -9 0 0 $angular bound for cells 10 and 11 
205 p 2.0593 9 0 0 $angular bound for cells 10 and 11 
206 p 2.1443 -9 0 0 $angular bound for cells 12 and 13 
207 p 2.1443 9 0 0 $angular bound for cells 12 and 13 
208 p 2.2286 -9 0 0 $angular bound for cells 14 and 15 
209 p 2.2286 9 0 0 $angular bound for cells 14 and 15 
210 p 2.3120 -9 0 0 $angular bound for cells 16 and 17 
211 p 2.3120 9 0 0 $angular bound for cells 16 and 17 
212 p 8.9813 -9 0 0 $angular bound for cells 18 and 19 
213 p 8.9813 9 0 0 $angular bound for cells 18 and 19 
214 p 2.6218 -9 0 0 $angular bound for cells 22 and 23 
215 p 2.6218 9 0 0 $angular bound for cells 22 and 23 
c 
************************************************************************
****** 
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c pelvis (700) 
101 pz -22 
102 pz -20 
103 pz -18 
104 pz -16 
105 pz -14 
106 pz -12 
107 pz -10 
108 pz -8 
109 pz -6 
110 pz -4 
111 pz -2 
112 pz 0 
113 pz 3 $top of L5 
114 pz 4 
115 pz 7 $top of L4 
116 pz 8 
117 pz 11 $top of L3 
118 pz 12 
119 pz 15 $top of L2 
120 pz 16 
126 pz 19 $top of L1 
121 py 1 
122 py 3 
123 py 5 
124 py 7 
125 py 9 
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127 py 11 
704 sq 0.00694 0.00694 0 0 0 0 -1 0 1 0 
705 sq 0.00783 0.00783 0 0 0 0 -1 0 0.2 0  
c pelvis (700) 
c spine (800) 
800 pz 20 $ 701 and 800 lower, 800 and 102 middle 
801 pz 62.8 $ 102 and 801 upper 
802 sq 0.25 0.16 0 0 0 0 -1 0 9.50 0 $ mid, lower 
803 sq 0.25 0.16 0 0 0 0 -1 0 5.45 0 $ upper 
804 rcc 0 0 -24 0 0 70 16.229999 $outer bound of torso 
805 rcc 8.1 0 -54 0 0 30 7 $left leg top 
806 rcc -8.1 0 -54 0 0 30 7 $right leg top 
807 rcc 8.1 0 -94 0 0 40 5 $left leg bottom 
808 rcc -8.1 0 -94 0 0 40 5 $right leg bottom 
809 sph 0 0 61.000001 10 $head 
810 rcc 0 0 46 0 0 5 5 $neck 
811 box -13.1 5 -99 10 0 0 0 -30 0 0 0 5 $right foot 
812 box 3.1 5 -99 10 0 0 0 -30 0 0 0 5 $left foot 
813 rcc 13.05 0 42.818 38.888 0 -38.89 4.5 $left arm 
814 rcc -13.05 0 42.818 -38.888 0 -38.89 4.5 $right arm 
815 sph 6 0 -6.35 1.32 $left ovary 
816 sph -6 0 -6.35 1.32 $right ovary 
817 box -6 -3 -2.54 12 0 0 0 -3 0 0 0 12.7 $small and large intestine 
818 rcc 0 0 -131 0 0 30 101 $concrete slab 
819 sph 4.39 -1.5 14.550001 4.39 $stomach wall outer 
820 sph 4.39 -1.5 14.550001 3.75 $stomach wall inner 
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c 
************************************************************************
****** 
 
c ********************************Data 
Cards************************************ 
c note:  soft tissue and bone composition from ORNL anatomy model 
m1 82000 1 $lead 
m3 26000 0.7455 25000 0.01 28000 0.07 24000 0.17 6000 0.00075 14000 0.00325  
     7000 0.0005  
     $stainless steel 301 (approx.) 
m4 7000 0.78 8000 0.21 18000 0.01 $air 
m6 1000 -0.035 6000 -0.16 7000 -0.042 8000 -0.445 11000 -0.003 15000 -0.095 
     16000 -0.003 12000 -0.002 20000 -0.215  $bone  
m7 1000 0.0990  
     6000 0.7723   
     7000 0.0396  
     8000 0.0495  
     9000 0.0198  
     20000 0.0198 $ICRU 99 tissue eq. plastic (A-150) 
m8    1001.      -0.0221     $  CONCRETE  
      6000.      -0.002484   
      8000.      -0.574930  
      11000.     -0.015208   
      12000.     -0.001266  
      13000.     -0.019953   
      14000.     -0.304627   
      19000.     -0.010045  
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      20000.     -0.042951   
      26000.     -0.006435  
c Source definition 
mode p 
sdef pos=d1  erg=0.662 par=2 
si1 L 21.23 0 -21.23   21.23 0 -8.79   21.23 0 0   21.23 0 8.79  
     21.23 0 21.23  
     -21.23 0 -21.23   -21.23 0 -8.79   -21.23 0 0   -21.23 0 8.79  
     -21.23 0 21.23 
     0 21.23 -21.23   0 21.23 -8.79   0 21.23 0   0 21.23 8.79  
     0 21.23 21.23 
     0 -21.23 -21.23   0 -21.23 -8.79   0 -21.23 0   0 -21.23 8.79  
     0 -21.23 21.23  
sp1 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05  
     0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05  
c Tally Definition 
f6:p 720 721 722 723 724 725 726 727 750 751 752 753 754 755 756 757  
     758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 800 801 
     802 803 804 816 817 818 820 
nps 5000000   
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Appendix II: MCNP Input file 360 Gamma Cloud Source (data card only) 
c ********************************Data 
Cards************************************ 
c note:  soft tissue and bone composition from ORNL anatomy model 
m1 82000 1 $lead 
m3 26000 0.7455 25000 0.01 28000 0.07 24000 0.17 6000 0.00075 14000 0.00325  
     7000 0.0005  
     $stainless steel 301 (approx.) 
m4 7000 0.78 8000 0.21 18000 0.01 $air 
m6 1000 -0.035 6000 -0.16 7000 -0.042 8000 -0.445 11000 -0.003 15000 -0.095 
     16000 -0.003 12000 -0.002 20000 -0.215  $bone  
m7 1000 0.0990  
     6000 0.7723   
     7000 0.0396  
     8000 0.0495  
     9000 0.0198  
     20000 0.0198 $ICRU 99 tissue eq. plastic (A-150) 
m8    1001.      -0.0221     $  CONCRETE  
      6000.      -0.002484   
      8000.      -0.574930  
      11000.     -0.015208   
      12000.     -0.001266  
      13000.     -0.019953   
      14000.     -0.304627   
      19000.     -0.010045  
      20000.     -0.042951   
      26000.     -0.006435  
c Source definition 
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mode p 
sdef x=d1 y=d2 z=d3 cel=222 erg=0.662 par=2 
si1 H -101 101 
sp1 0 1 
si2 H -101 101 
sp2 0 1 
si3 H -100.9999999 271.76999999 
sp3 0 1   
c Tally Definition 
f6:p 720 721 722 723 724 725 726 727 750 751 752 753 754 755 756 757  
     758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 800 801 
     802 803 804 816 817 818 820 
nps 5000000  
101 
 
Appendix III: MCNP Input file 360 Gamma Ground Source (data card only) 
c ********************************Data 
Cards************************************ 
c note:  soft tissue and bone composition from ORNL anatomy model 
m1 82000 1 $lead 
m3 26000 0.7455 25000 0.01 28000 0.07 24000 0.17 6000 0.00075 14000 0.00325  
     7000 0.0005  
     $stainless steel 301 (approx.) 
m4 7000 0.78 8000 0.21 18000 0.01 $air 
m6 1000 -0.035 6000 -0.16 7000 -0.042 8000 -0.445 11000 -0.003 15000 -0.095 
     16000 -0.003 12000 -0.002 20000 -0.215  $bone  
m7 1000 0.0990  
     6000 0.7723   
     7000 0.0396  
     8000 0.0495  
     9000 0.0198  
     20000 0.0198 $ICRU 99 tissue eq. plastic (A-150) 
m8    1001.      -0.0221     $  CONCRETE  
      6000.      -0.002484   
      8000.      -0.574930  
      11000.     -0.015208   
      12000.     -0.001266  
      13000.     -0.019953   
      14000.     -0.304627   
      19000.     -0.010045  
      20000.     -0.042951   
      26000.     -0.006435  
c Source definition 
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mode p 
sdef sur=821 pos=0 0 -101.000001 RAD=d1 erg=0.662 par=2 
si1 H 0 101 
sp1 0 1 
c Tally Definition 
f6:p 720 721 722 723 724 725 726 727 750 751 752 753 754 755 756 757  
     758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 800 801 
     802 803 804 816 817 818 820 
nps 5000000  
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Project Title Testing of the StemRad
® 360 GammaTM Personal 
Protection Device 
PNNL Project Manager Mark K. Murphy, Radiation Measurements & 
Irradiations Group 
PNNL Project/Proposal 
Number 
66845 
C stomer: StemRad LTD 
Customer Point of Contact Dr. Oren M. Milstein – 
StemRad LTD 
oren@stemrad.com 
U.S. Office: 
228 Hamilton Ave. Palo Alto, CA 
94301 650-388-9112 (Tel)   650-
388-9120 (Fax) 
 
BACKGROUND 
StemRad LTD is a private company based in Tel Aviv, Israel, with offices in Palo 
Alto, CA. StemRad LTD developed a product called the StemRad® 360 
GammaTM, which is a “personal protection device” that is worn like a belt, and 
that wraps around the hips in order to shield the bones that contain a significant 
percentage of the body’s bone marrow. The objective is to conserve enough 
viable bone marrow from an otherwise deadly radiation dose to allow 
regeneration of bone marrow and survival of the individual. 
 
StemRad LTD staff Dr. Oren M. Milstein (CSO) and Daniel Levitt (CEO), and 
their U.S. consultant Dr. Kenneth Kase, visited staff from the Radiation 
Measurements & Irradiations Group at Pacific Northwest National Laboratory 
(PNNL) on May 9, 2014, to see the irradiation and dosimetry processing labs 
and to discuss details of the desired TLD measurements within phantom 
wearing the StemRad® 360 GammaTM device. Discussions during that visit, 
and numerous email communications afterwards, resulted in the final 
protocols used. 
CUSTOMER REQUIREMENTS AND EXPECTATIONS 
StemRad’s desire was for PNNL to perform irradiations of the RANDO® male 
phantom that would result in an approximate simulation of a radiation 
exposure of an individual to a “cloud” of Cesium-137 (Cs-137) radioactivity, 
while still being consistent with the irradiation geometry of previous phantom 
irradiations conducted by StemRad in Israel. 
This source-phantom irradiation geometry could also simulate the radiation dose to an 
individual walking and turning numerous times in an enclosed environment that 
contains multiple sources at various heights relative to the individual. After discussions 
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between StemRad and PNNL staff, StemRad selected the source-phantom geometry 
options listed in 
 Table 1. Table 1. RANDO® and Cs-137 Source Irradiation Geometry Selected By 
StemRad for Subject Testing 
 
RAND
O 
Height 
* Off 
Floor 
 
Source 
Movemen
t# 
Number 
of Source 
Positions 
and 
Angles 
Dwel
l 
Times 
at 
Each 
Angle 
Dose to 
RANDO 
Reference 
Point* at Each 
Source 
Position 
RANDO
- 
Source 
Distanc
e at 0˚ 
†  
170 
cm 
Vertical 
in straight 
line 
 
-45˚, -22.5˚, 0˚, 
+22.5˚, +45 ˚ 
 
Equal 
Varying 
(due to 
varying 
source 
distance) 
 
130 cm 
*  Measured relative to the reference point, located on the top surface of slice 29. 
#   The maximum source height possible with existing equipment is 304 cm. 
† This distance, combined with RANDO® height and straight line source 
movement, results in lowest position of source being ~40 cm off floor (and 
thus ~4.5% floor scatter at that position) and highest position being 300 cm off 
floor. 
 
 
StemRad also desired that the irradiations be done with TLDs located in tissue 
and bone within the hip and abdominal areas, including within bone marrow in 
the hip bones and vertebrae and within the GI tract. Of course, irradiations 
would be performed for the two cases of StemRad® 360 GammaTM device ON 
and OFF. 
 
PROJECT OBJECTIVES 
The project objective is to provide data that shows the effectiveness 
(decrease in dose to hip and abdominal area) of the StemRad® 360 
GammaTM device for the approximate simulation of a “cloud” of Cs-137 
radioactivity. 
 
TEST EQUIPMENT 
The equipment utilized during this project are listed in Table 2. PNNL’s male 
RANDO® phantom, manufactured by Alderson Corp., was used for the 
irradiations. The RANDO® man represents a 175 cm (5’9”) tall and 73.5 kg (162 
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lb.) male figure. It does not have arms or legs. The phantom is constructed with a 
real human skeleton which is cast inside soft tissue- simulating material. Lungs 
are molded to fit the contours of the natural rib cage. The air space of the head, 
neck and stem bronchi are duplicated. The phantom is sliced at 2.54-cm intervals 
to allow access to various parts and, in particular, to the cavities for radiation 
detectors.  Each slice contains approximately 40 of these cavities, each 4.8 mm 
diameter in a 
3.5 cm grid pattern. 
 
 
Equipment Model 
Serial 
Numbe
r 
 
U
s
e 
Calib 
Expiratio
n Date 
StemRad® 360 
GammaTM belt, Small-
Tall size 
SR36001
9 
Allow measurement of 
effectiveness of belt in Cs-137 
field 
N/A 
Alderson RANDO® 
anthropomorphic phantom, 
with real skeleton 
 
N/A 
Allow measurement of 
effectiveness of belt in 
reducing radiation dose 
rate to specific regions of a 
human 
 
N/A 
4.85 Ci Cs-137 Source, 
triple encapsulation 
318-030 Irradiations of RANDO
® 
phantom with and without 
belt 
02/201
6 
Capintec Model PR-18 
ionization chamber 
5889 
Both calibration and real-
time monitoring of 
radiation field 
04/201
6 
Keithley Model 617 
electrometer 
383823 
Collect signal from 
ionization chamber 
06/201
5 
Temperature probe 
TNFL1
- 
0001 
Temperature and pressure 
values allow corrections to 
ionization signal due to air 
density 
02/201
6 
Barometric pressure 
PEEW
1- 
0001 
02/201
6 
 
Timer 
SWCC
1- 
0001 
Provide accurate 
durations of radiation 
exposure for each 
position and total 
duration. 
 
02/201
6 
Harshaw TLD-700 Lithium- 
fluoride Thermoluminescent 
Dosimeters (TLD) 
chips(0.32mm x 0.32 mm x 
0.9 mm) 
 
StemRa
d 
set 
Placed within RANDO® 
cavities, allows measurement 
of total integrated radiation 
dose 
 
Cali
b 
4/201
5 Harshaw Model 5500 
TLD Reader 
WD3369
7 
Allows automated readout 
and analysis of TLDs 
N/A 
Automated turntable at 1 
rpm, attached to the top of 
aluminum frame on a 
hydraulic cart 
 
N/A 
Allows continuous 
rotation of RANDO 
phantom 
 
N/A 
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The Cs-137 source used has a current activity of 4.85 Ci, and is contained within 
three layers of encapsulation consisting of a total of 0.078” stainless steel and 
0.125” aluminum.  This 
 
Table 2.  Equipment Utilized for StemRad® 360 GammaTM Belt Irradiations on 
Phantom 
 
results in the elimination of the beta particle part of the spectrum associated 
with the unencapsulated nuclide, and only the gamma spectrum is seen 
(peaks at 662 keV). 
 
PREPARATION FOR TESTING 
Even though the RANDO® phantom already contained approximately 40 cavities in 
each slice, StemRad desired dose information at additional locations, especially in 
bone. In order to determine the exact locations for these additional cavities, 
StemRad used ImageJ software to construct 3D models of the red bone marrow 
within the RANDO® phantom.  The 2D images of each slice face (provided by PNNL) 
were loaded into the segmentation editor of ImageJ as image stacks and the red 
bone marrow regions were highlighted as regions of interest and interpolated to 
form 3D volumes of the red bone marrow within the RANDO® slices. Because of the 
relative spatial uniformity of the spinal column, the vertebral volumes were assigned 
one TLD cavity only for each slice (totaling 7 cavities). The remaining 33 cavity 
locations were then identified by calculating the center of masses of 33 equal 
volumes of the pelvic red bone marrow within these slices. This StemRad-developed 
method allows StemRad to match absorbed doses in these cavities to specific masses 
of red bone marrow within the lower spine and pelvis. At StemRad’s direction, PNNL 
drilled 40 additional cavities at the identified locations, in 11 of the slices that 
involved the hip and abdominal area (slices 22-32). Two images of each of these 11 
slices are provided in Appendix A: one image with StemRad’s labeled locations for 
desired TLD locations, and another image showing PNNL’s labeled cavities into which 
TLDs were inserted for the RANDO® irradiations – for a total of 22 images. StemRad 
determined that the 40 TLD cavity locations which required drilling into bone are 
representative of red bone marrow tissue and the other 52 TLD cavity locations are 
representative of other tissues in the abdominal region. 
Refer to Appendix C to discern the tissue associated with each measurement 
location. 
 
Another modification to the RANDO® phantom was to mill down “high spots” at the 
interfaces of about six of the phantom slices. This was needed in order to make the 
assembled phantom much more stable, and ensure that the slices in the spinning 
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phantom would not shift during the 8-10 hour irradiation. 
 
In order to provide secure attachment of RANDO® to the turntable, and still 
maintain natural thigh shape, mass, and radiation scatter; thigh extensions were 
fabricated from tissue-equivalent polymer and were attached to the turntable, and 
allowed attachment to RANDO® thighs using polymer dowels. The turntable was 
secured to the very edge of a hydraulic cart that could raise RANDO® from 
approximately 60 cm to 200 cm in height. 
 
Because source-to-RANDO and floor-to-RANDO distances were important, as were 
the irradiation angles, it was required to have a RANDO reference point. StemRad 
selected a point near the middle of the RANDO® torso, located on the top surface of 
slice #29 and at the geometric center of that slice, which is at the point of an 
existing TLD cavity (see slice 
#29 image in Appendix A). To ensure that the z-axis of RANDO® rotated exactly 
relative to this selected reference point on slice #29, first the polymer thigh 
extensions were placed on a level surface, then RANDO® slices were stacked on top of 
the polymer thigh extensions until slice #29 was complete (and using carpenter’s 
level, ensuring slice surfaces stayed level). A carpenter’s plumb-bob – suspended 
from above – was lowered to slice #29 and centered on the reference point. Then the 
top slice was removed, the plumb-bob lowered and rotation axis location on this next 
slice labeled, and this repeated until axis of rotation on slices 29-34 and the polymer 
thigh extension were all labeled.  This marked axis of 
rotation on the polymer thigh extension allowed it to be aligned on turntable exactly 
as desired to allow RANDO® to rotate relative to the slice #29 reference point. When 
RANDO was stacked all the way to his neck, the plumb-bob was again used to mark 
the point of rotation on the top of each slice (slices 10-30), and it was observed that 
this axis of rotation consistently stayed aligned with the same central cavity/plug on 
each slice. 
 
In order to provide a secure anchor at the top of the spinning RANDO®, a ¾-inch 
piece of plywood with a 7/8-inch hole in the center was screwed to the top of 
RANDO® (the slice representing the base of the neck), and a 7/8-inch wood dowel 
(secured by an overhead arm) was inserted into the hole. The overhead arm is 
constructed of hollow, thin-walled aluminum frame, which resulted in less than 0.4% 
scatter of radiation field in direction of RANDO® (this was measured by placing the 
aluminum frame next to a Model RO-20 radiation survey meter in the Well Room Cs-
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137 field). 
 
In order to allow movement of the Cs-137 source vertically during RANDO® 
irradiations, a thin-walled PVC pipe (cut in half to form a half-pipe) was used to hold 
the source, and this source holder was raised to a maximum height of 300 cm by 
being attached to a Genie Lift. The Genie Lift is a strong, low mass fork lift that was 
manually operated from 300 cm using a long rod (allowing operator to stay outside 
high radiation fields). 
 
The “fit” or exact positioning of the 360 GammaTM belt on the RANDO® phantom to 
StemRad’s desired specifications was accomplished by PNNL staff placing the belt on 
RANDO®, taking digital photos from numerous angles, emailing the photos to 
StemRad staff, and adjusting the belt based on feedback from StemRad. This process 
took over a week’s time because the medium-sized belt was found to be slightly too 
large for RANDO®, and so StemRad shipped their small-sized belt. Based on the 
photos provided to StemRad (see Figure 1), the small-sized belt provided an 
acceptable fit according to StemRad. This acceptable fit was defined as the back of 
the belt spanning between slice 24.5 and slice 33.5, and the front of the belt spanning 
between slice 25.3 and slice 32.3, which resulted in the midpoint of belt span on both 
front and back being well within 0.5 cm of the desired reference point of slice 29.0 
(top of slice 29). 
 
The RANDO® cavities the TLDs would occupy were cleaned with alcohol to ensure no 
luminescent debris would get on TLD chips, then these cavities were labeled with 
marked masking tape to ensure accurate TLD placement and documentation. 
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Figure 1. Photos of small-sized belt on RANDO® phantom. These photos allowed 
StemRad staff to verify that the fit met with their specifications. 
 
TEST PROTOCOL USED 
The TLD and phantom preparation, source-phantom geometry, and irradiation 
protocol was as follows: 
 TLD-700 LiF TLDs were used, and analyzed with a Harshaw Model 5500 
reader. Before each use/irradiation, the TLDs were reader annealed using a 
linear time- temperature profile (TTP) with a heating rate of 10°C/s, starting 
at 50°C and reaching a maximum temperature of 300°C, for a total heating 
time of 43 seconds. The reader anneal was followed by a low temperature 
oven anneal at 80°C for 24 hours to reduce the abundance of short half-life 
traps in the TLD crystal and thus reduce fading of signal. 
 Within two days prior to RANDO® irradiations, at one slice at a time the TLDs 
were loaded into desired RANDO® cavities (3 TLDs per cavity) at the center 
height within the phantom slice, and the resulting voids at the top and bottom 
of the cavities were filled with unit density plugs. The total number of test 
cavities involved was 92, resulting in 276 TLD test chips, which did not count 
the TLD chips used for controls and calibration set. TLD location is 
documented as to slice#, cavity#, wheel#, and wheel position# (there were 7 
separate wheels or circular cartridges used for automated readout of TLDs, 
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with 50 slots in each wheel to accommodate 50 TLD chips). 
 An additional cavity at shoulder level of RANDO® (slice 13) was loaded with 
TLDs for both irradiations. This was in order to allow comparison of total 
integrated dose for belt ON and belt OFF scenarios and make any corrections if 
necessary. The cavity used was only approximately 1 cm depth in tissue, and 
mid-way between shoulders, and would not be impacted by presence or 
absence of StemRad belt. 
 In addition, 50 reader calibration chips, 12 QC chips, 12 blank chips and 40 
spares were used to support the measurement process. 
 The phantom slices were then stacked on top of turntable to complete the 
phantom assembly, and well secured with long strips of industrial adhesive 
tape. Then top anchor was put in place. 
 The RANDO®/Turntable/Cart assembly was then rolled into the Low Scatter 
Facility and placed at desired location near center of the room. The room is 
approximately 8 x 9 x 10 meters in size. 
 The Monitoring Chamber was then centered at RANDO® reference height 
(top of slice 29) and at 14.5 cm from RANDO® surface (right side of RANDO®) 
and secured. This chamber would provide gamma field intensity monitoring 
in real-time, and allow immediate verification at each of the 5 source 
positions that source radiation field was at correct intensity relative to 
RANDO®. This would provide backup data for the passive monitoring (TLDs in 
cavity in slice 13). It should be noted here that the measured tissue dose 
from chips in slice 13 is not expected to match the tissue dose inferred from 
the air kerma measured by the monitoring chamber due to the shielding 
provided by the phantom during rotation. 
 RANDO/cart was then raised until top of slice 29 was at predetermined 
irradiation height of 170 cm. 
 Source holder (without source) was raised to each of the 5 positions, and both 
source height and RANDO-Source distances were measured and verified (See 
Table 3 for resulting angles and distances). 
 Video monitoring was then turned on, as well as turntable at 1 rpm. 
 The source holder was set at the first irradiation position (-45 degrees = 40 
cm height) and, using a 180 cm handling tool, the source was quickly 
transferred from its storage container to the source holder. The stopwatch 
was started when source was within the PVC holder, and the PVC lid flipped 
into position. Photos in Figures 2a and 2b provide view of actual setup just 
prior to irradiation #2. 
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 After the preselected irradiation duration had elapsed (1 hour 36 minutes), 
using a 
3.5 meter rod outside the high radiation area, the Cs-137 source is quickly 
cranked vertically to the next highest position. This movement is 
accomplished within about 15-20 seconds. 
 After each predetermined irradiation duration (1 hour 36 minutes) the 
source is moved to next irradiation position for a total of 5 positions listed 
in Table 3. 
 As the irradiation is completed at the last source position (highest position, + 
45 degrees and 300 cm height), the source is quickly lowered to the lowest 
position (~25 seconds) and then transferred back to its shielded storage 
container away from RANDO®   (~ 10 seconds). 
 The phantom/cart is then lowered and rolled back to the dosimetry lab. 
 At some time prior to TLD analysis, RANDO® is dismantled one slice at a 
time and TLDs removed from its cavities. The TLDs are placed into “wheels” 
(Trays used in automated reader), and TLD location is documented as to 
slice#, cavity#, wheel #, and wheel position#. 
 At the predetermined TLD post irradiation fade time (~ 2-4 days), the 
loaded TLD reader wheels were placed in the TLD Reader for readout and 
analysis. 
 Reader Calibration was accomplished by reading chips exposed under CPE 
conditions behind 6.9 mm of PMMA plastic in a chip irradiation jig mounted 
on a 30 cm x 30 cm x 15 cm PMMA phantom. The chips were exposed with 
their front face located at a distance of 3 meters from the source, using a J.L 
Shepherd Cs-137 beam irradiator to achieve a delivered air kerma 
corresponding to D(10) = 10 mGy, based on CK = 1.21 (ANSI/HPS N13.11-
2009). The calibration chips were annealed, exposed and read at the same 
time as the test chips exposed in phantom. 
 The entire process was repeated for the second RANDO® irradiation. 
 The TLD results were then populated into a spreadsheet and resulting dose 
levels calculated. The data results included providing the ratio of the mean 
dose from each RANDO® cavity for both belt ON/OFF scenarios in order to 
provide a measure of belt effectiveness to Cs-137 field. 
Table 3. Angles, distances and exposure rates associated with RANDO and Cs-137 
source. 
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Sourc
e 
Positio
n 
Source 
Height Off 
Floor (cm) 
Source-Slice 
29 
Reference 
Distance 
(cm) 
Source-
RANDO Z-
axis 
Distance 
(cm) 
mR/h in 
AIR 
(slice 29) 
mR in 1.6 
hrs in AIR 
(slice 29) 
+45˚ 300 184 130 37
9 
606 
+22.
5˚ 
224 141 130 64
5 
103
2 
0˚ 170 130 130 75
9 
121
4 
-
22.5˚ 
116 141 130 64
5 
103
2 
-45˚ 40 
(~4.5% 
scatter) 
184 130 39
6 
634 
* Air-Kerma, Gy, is obtained by multiplying Exposure, R, by 8.78E-3 Total 
Exposure: 4.518 R 
*Total Air-Kerma: 3.967 cGy  
 
 
 
 
 
 
Figure 2a. Photo 
of wide view of 
actual setup just 
prior to 
irradiation Run 
#2, with RANDO 
(belt ON) on left, 
and white PVC 
source holder on 
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bottom right. 
 
 
 
 
Figure 2b. Photos of actual setup just prior to irradiation Run #2, showing sample 
Cs-137 source (polished aluminum) in its white PVC holder, RANDO rotating with 
belt ON, and monitoring chamber. 
 
DATA RESULTS 
 
A copy of the irradiation datasheet, showing the verified angles, distances, irradiation 
durations, and monitoring chamber signal is provided in Appendix B.  For any given 
run, the real-time monitoring chamber data indicated that the signals for the paired 
angles (±22.5 ˚ and ±45 ˚) were within 1.5% of each other when the known ~4.5 % 
scatter at -45 ˚ position is accounted for. Comparing the monitoring chamber signals 
for run#1 and run#2 shows the dose rates for the two runs were within 1.5% of each 
other. This is consistent with the TLD results from slice 13, which indicate the total 
doses for run#1 and run#2 were within about 1%. This agreement, along with 
verifying the distances before each run, provides assurance that for run#1 and run#2 
RANDO® experienced the same irradiation angles, distances, dose rates, and total 
delivered dose. 
 
Appendix C contains the spreadsheet that includes the average measured absorbed 
dose in tissue for each TLD cavity, for both Belt Off and Belt On conditions. Also 
included are the ratios of absorbed dose for Belt On and Belt Off conditions for these 
tissue types, as well as the associated standard deviations of the data. Table 4 
summarizes these measured absorbed dose values for the various tissue types. Table 
5 summarizes the Belt On/Belt Off dose ratio for each of the regions or tissue types. 
 
The symmetry in the X-Y plane for doses measured within RANDO® without the 
shielding belt, as indicated by the values in the spreadsheet in Appendix C, is due to a 
combination of 
 
 
Table 4. Summary of measured absorbed dose in tissue by body region or tissue 
type, for both Belt OFF and Belt ON conditions. 
 
Body Region/Tissue Type Absorbed Dose – Belt OFF 
Mean * %SDEV  † 
Absorbed Dose – Belt ON 
Mean * %SDEV # 
Bone Marrow - Hip 2797 mrad 3.0 1637 mrad 15.4 
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Bone Marrow - Vert 2770 mrad 3.8 1922 mrad 17.7 
Bone Marrow – Hip & Vert 2792 mrad 3.2 1687 mrad 17.0 
GI Tract 2818 mrad 3.2 2081 mrad 10.4 
Ovaries** 2693 mrad 0.5 1765 mrad 0.1 
Combined 2.80 rad 
(2.80 cGy) 
3.2 1.90 rad 
(1.90 cGy) 
16.5 
* Dose values are the integrated absorbed dose relative to tissue. 
† In addition to the high accuracy and precision of the TLDs, these tight standard 
deviations are due to a combination of symmetric source-RANDO geometry, the 
fact RANDO was irradiated from all sides, the relatively large distance of the source 
approximated a point-source geometry and minimal variation in “in-air” dose rate 
across RANDO volume, and the penetrating ability of Cs-137 gamma spectrum in 
tissue. 
# The reason these standard deviations are as good as they are, is due to the same 
combination of reasons above; but deviation is greater because the fact that not all 
the TLD locations were shielded fully by the shielding belt for the entire exposure. 
** These would be the approximate ovary locations if this RANDO was female 
based on anatomical markers. 
Table 5. Summary of the Belt ON/Belt OFF dose 
ratio for each of the regi  or tissue 
types. 
 
Body Region/ 
Tissue Type 
 
Min 
Ratio 
 
Max 
Ratio 
Belt ON/Belt OFF 
Dose Ratio 
Mean %SDEV 
Bone Marrow - Hip 0.42 0.76 0.59 17.0 
Bone Marrow - 
Vert 
0.49 0.87 0.70 19.4 
Bone Marrow – Hip & Vert 0.42 0.87 0.61 18.6 
GI Tract 0.62 0.87 0.74 9.8 
Ovaries 0.652 0.659 0.656 0.7 
Combined 0.42 0.87 0.68 16.5 
 
 
the following: 
 
 The symmetry of the physical RANDO® (tissue and bone) in the X-Y dimension. 
 The symmetry of the effective density of RANDO in the X-Y dimension. 
 The symmetry in the X-Y dimension of the cavities containing TLDs. 
 The source distance, and thus dose rate, being equal for each pair of same-
symmetry TLD cavities. 
 RANDO® completing numerous rotations at a constant speed during exposure. 
 The fact that the axis of rotation for RANDO® was very near the geometric 
center of each slice, especially the slices containing TLDs. 
 
Measurements of the Cs-137 radiation field at 170 cm height and distances of 120 cm 
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and 130 cm were also performed without RANDO® in place in order to provide the 
exposure rate and air-kerma rate “free-in-air”. The measured exposure rates of 759 
mR/h (0.666 cGy/h Air-kerma rate) at the 130 cm reference distance, and the 889 
mR/h (0.781 cGy/h Air- kerma rate) at 120 cm indicates, as expected, that the field 
follows 1/d2. This will allow in- air dose rates to be calculated for any location in free 
space, so any location where RANDO® volume could reside. This would be useful to 
compare in-air dose rate versus tissue or bone dose rate (and therefore total 
integrated dose) at any point for a stationary RANDO® phantom. 
 
MEASUREMENT UNCERTAINTIES 
 
The radiation measurement uncertainties that PNNL’s Radiation Measurements & 
Irradiations group calculate for their operations, using GUM Workbench software, are 
consistent with NIST Technical Note 1297 (1994), as well as a document produced by 
Working Group 1 of the Joint Committee for Guides in Metrology in 2008 titled 
“Evaluation of Measurement Data - Guide to the Expression of Uncertainty in 
Measurement”. The measurement uncertainty values that were expected to be of 
most interest to StemRad were those that involved the MEASURED AIR-KERMA RATE 
(and integrated AIR-KERMA) at the location where RANDO would be placed, the 
resulting MEASURED ABSORBED DOSE to RANDO TISSUES, and the BELT ON/BELT OFF 
MEASURED DOSE RATIOS for these same 
tissue regions. 
 
Uncertainty in the Measured Air-Kerma: Because StemRad may desire to use the 
testing results to create factors that convert from a known Exposure rate (R/time) or 
Air-Kerma rate (Gy/time) of a field, to the dose within RANDO (wearing the StemRad 
belt) placed in such a field (for example, Absorbed Dose in specified organs or 
Effective Dose Equivalent), the measurement uncertainties associated with these 
Exposure and Air-Kerma parameters (See Table 3) would be helpful. The expanded 
uncertainty associated with these Exposure and Air-Kerma values were calculated to 
be ± 1.15% at the 67% confidence level (k = 1), and 
± 2.3% at the 95% confidence level (k=2). 
 
Uncertainty in TLD Measured Dose: As can be expected, the main uncertainty 
components involve the precision of the readout values of the TLD chips. Given that 
the TLD system was calibrated prior to RANDO® irradiation using one of PNNL’s 
calibrated Cs-137 fields, the uncertainties in the resulting Gy and Gy/hr values 
measured within RANDO® are not influenced by the source-RANDO geometry 
(distances and angles). As can be seen on the spreadsheet in Appendix C, which 
details the TLD measurement results for the various regions or tissue types, for the 
Belt Off irradiation the standard deviation of the measured absorbed dose varied 
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between 0.5% and 3.8%, with the standard deviation for all tissues combined being 
3.2% (See Table 4). Propagating all uncertainties, the total expanded uncertainty for 
the quoted ABSORBED DOSES within the RANDO® cavities at the specified locations 
with Belt Off was calculated to be ± 2.4% at the 67% confidence level (k = 1), and 
± 4.8% at the 95% confidence level (k = 2). 
 
For the Belt On irradiation, the standard deviation in the measured absorbed dose 
varied between 0.1% and 17.7%, with the standard deviation for all tissues combined 
being 16.5% (See Table 4). Propagating all uncertainties , the total expanded 
uncertainty for the quoted ABSORBED DOSES within the RANDO® cavities at the 
specified locations with Belt On was calculated to be ± 3.1% at the 67% confidence 
level (k = 1), and ± 6.2% at the 95% confidence level (k = 2). 
 
For the Belt On/Belt Off dose ratios, the standard deviation varied between 0.7% 
and 19.4%, with the standard deviation for all tissues combined being 16.5% (See 
Table 5). Propagating all uncertainties, the total expanded uncertainty for the Belt 
On/Belt Off dose ratios for cavities at the specified locations was calculated to be ± 
4.0% at the 67% confidence level (k = 1), and  ± 7.9% at the 95% confidence level (k 
= 2). 
 
The details in the various components of uncertainty and how they were propagated 
to arrive at the expanded uncertainty values above are provided in Appendix D. In 
addition to using the TLD chip readout accuracy and precision values described above 
(the main contribution to error), the overall expanded uncertainty takes into account 
other variables such as the physical measurement of the source-RANDO distances at 
the various angles, estimated Cs-137 source anisotropy, and the results of the quality 
control dosimetry in phantom slice 13. 
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APPENDIX A - StemRad’s provided photos (left) showing their desired X-Y coordinates 
for TLD cavities, and PNNL’s provided photos (right) showing resulting TLD cavities.  
RANDO® phantom slices 22-32. 
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Appendix B – StemRad Irradiation Data Sheet Copy 
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Appendix C: TLD Raw Data Results 
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Appendix D – Measurement Uncertainty Calculations 
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Appendix V: Dose Reduction data from MCNP simulations for selectively shielded 
organs using 360 Gamma shielding in various source geometries and photon energies 
 
Table 1: Average Organ Absorbed Dose Reduction for PNNL Experiment and MCNP 
Simulations with Various Source Geometries and Energies 
  Average 
Organ 
Absorbed 
Dose 
Reduction 
(%) 
 
   
Energy  Ovaries Intestines Stomach Total Body 
Bone 
Marrow 
662 keV PNNL 
experimental 
35 26* N/A 19 
662 keV PNNL MCNP 
simulation 
29 30 19 17 
 100% Cloud  30 30 21 17 
 90% Cloud - 
10% Ground  
27 28 21 17 
 80% Cloud - 
20% Ground  
23 26 22 16 
 70% Cloud - 
30% Ground  
20 24 22 15 
 60% Cloud - 
40% Ground  
17 22 23 14 
500 keV 50% Cloud - 
50% Ground  
14 20 23 13 
 40% Cloud - 
60% Ground  
11 17 24 12 
 30% Cloud - 
70% Ground  
8 15 25 11 
 20% Cloud - 
80% Ground  
6 12 26 10 
 10% Cloud - 
90% Ground  
3 9 28 8 
 100% 
Ground  
1 6 29 6 
 100% Cloud  29 22 17 15 
 90% Cloud - 25 21 18 14 
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10% Ground  
 80% Cloud - 
20% Ground  
22 20 18 14 
 70% Cloud - 
30% Ground  
19 18 19 13 
 60% Cloud - 
40% Ground  
17 17 19 12 
662 keV 50% Cloud - 
50% Ground  
14 15 20 11 
 40% Cloud - 
60% Ground  
11 13 21 10 
 30% Cloud - 
70% Ground  
8 12 22 9 
 20% Cloud - 
80% Ground  
6 10 23 8 
 10% Cloud - 
90% Ground  
3 8 25 6 
 100% 
Ground  
1 6 26 4 
 100% Cloud  24 22 17 14 
 90% Cloud - 
10% Ground  
21 21 17 14 
 80% Cloud - 
20% Ground  
18 19 18 13 
 70% Cloud - 
30% Ground  
16 18 18 12 
 60% Cloud - 
40% Ground  
13 16 19 11 
700 keV 50% Cloud - 
50% Ground  
11 14 19 11 
 40% Cloud - 
60% Ground  
8 12 20 10 
 30% Cloud - 
70% Ground  
6 10 21 9 
 20% Cloud - 
80% Ground  
4 8 21 7 
 10% Cloud - 
90% Ground  
2 6 22 6 
 100% 
Ground  
0 3 24 4 
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Appendix VI: MCNP Input Code for AstroRad Material Testing 
AstroRad Materials  
c Material of interest: C2H4 (70%) + cubic BN (30%) 
c 
************************************************************************
****** 
1 1 -1.129 -1 imp:p,n,h,#,s,a,d,t=1 $target 
2 3 -1.722 1 -2 imp:p,n,h,#,s,a,d,t=1 $candidate material  
3 2 -2.7 2 -3 imp:p,n,h,#,s,a,d,t=1 $Generic Orion Al shielding 10.7 g/cm^2 
4 0 3 -4 imp:p,n,h,#,s,a,d,t=1 $thin void 
5 0 4 -6 imp:p,n,h,#,s,a,d,t=1 $thin void 
6 0 6 imp:p,n,h,#,s,a,d,t=0 $outside universe  
c 
************************************************************************
****** 
 
c *********Surface 
Cards******************************************************** 
1 so 30 $target sphere outer bound 
2 so 35 $candidate material shell outer bound 
3 so 38.96000 $Al shell outer bound 
4 so 38.96001 $source surface 
6 so 38.96002 $outer bound of universe 
c 
************************************************************************
****** 
 
c ********************************Data 
Cards************************************ 
m1 1000 0.0990  
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     6000 0.7723   
     7000 0.0396  
     8000 0.0495  
     9000 0.0198  
     20000 0.0198 $ICRU 99 tissue eq. plastic (A-150) 
m2 13000 1 $Al 
m3 5000 1.208703  
     6000 4.991087  
     7000 1.208703  
     1000 9.982175 $C2H4 (70%) + cubic BN (30%)  
c Source definition 
phys:# 16000 
mode p n h # s a d t  
sdef sur=4 nrm=-1 erg=16000 par=8016 
c Tally Definition 
f6:p 1 
f16:n 1 
f26:h 1 
f46:# 1 
f56:s 1 
f66:a 1 
f76:d 1 
f86:t 1 
nps 1000000 
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Appendix VII: “Golda” Computerized Female Human Phantom Composition 
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